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CHAPTER I 
INTRODUCTION 
 
The development, homeostasis, and repair of mammalian tissues is 
ultimately governed by transcription factors that bind DNA and regulate the 
transcription of genes. The composite effect of transcription factors on gene 
expression can be assessed by analyzing transcriptomes, the set of all 
RNA molecules and their quantity in a single cell or population of cells. 
Different cell types express unique transcriptional programs, and this 
variation underlies the wide range of physical, biochemical, and 
developmental differences seen among various cells and tissues. By 
performing comparative analyses on the transcriptional programs of 
different types of cells or tissues, researchers can gain a deeper 
understanding of what constitutes a specific cell type and how changes in 
the transcription of genes contribute to development and disease. In this 
chapter, the p53 family of transcription factors and their functions in 
mammalian tissues will be reviewed, with an emphasis on one family 
member, p73, and one specific tissue, the skin; and epidermal 
differentiation, homeostasis, and wound healing will be introduced. This 
dissertation primarily focuses on the role of p73 in basal keratinocytes of 
the skin and identifies p73 as a regulator of epidermal wound healing and 
keratinocyte gene expression. 
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p53 Family of Transcription Factors  
 
Discovery 
In 1979, p53 was discovered as a 53 kDa protein in complex with 
SV40 large T antigen in SV40-transformed cells (Lane and Crawford, 
1979). Subsequent studies over several decades demonstrated that p53 is 
a tumor suppressor (Baker et al., 1989; Donehower et al., 1992; Malkin et 
al., 1990; Srivastava et al., 1990) and is the most frequently mutated gene 
in human cancers (Kandoth et al., 2013). p53 has been dubbed the 
“guardian of the genome” by its co-discoverer (Lane, 1992), Sir David 
Lane, for the important role it plays in coordinating the cellular response to 
DNA damage, through regulation of cell cycle arrest (Baker et al., 1990; 
Diller et al., 1990; Mercer et al., 1990), induction of apoptosis (Michalovitz 
et al., 1990; Yonish-Rouach et al., 1991), and cellular senescence (Serrano 
et al., 1997). The tumor suppressive activity of p53 is mediated by its ability 
to function as a sequence-specific transcription factor (Fields and Jang, 
1990; Pietenpol et al., 1994; Raycroft et al., 1990) that binds and regulates 
the expression of target genes such as CDKN1A (which encodes p21, the 
cyclin-dependent kinase inhibitor) (el-Deiry et al., 1993; Kandoth et al., 
2013) and MDM2 (Barak et al., 1993; Wu et al., 1993). Mice lacking p53 
(p53-/-) have a normal appearance, but develop a variety of spontaneous 
tumors by six months of age (Donehower et al., 1992). Similarly, 
inactivating mutations in human p53 gene (TP53) cause Li-Fraumeni 
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syndrome (Malkin et al., 1990; Srivastava et al., 1990), an autosomal 
dominant-inherited cancer predisposition syndrome that is characterized by 
the development of a variety of childhood and adult tumors. 
It took almost two decades for a homologue of p53 to be identified. 
In 1997, Kaghad and colleagues (Kaghad et al., 1997) identified p73 as a 
false positive in a cDNA screen for sequences corresponding to the 
protein-binding domain of the insulin receptor substrate 1 (IRS-1; involved 
in insulin signaling). The investigators found that the gene of interest had 
63% amino acid identity with the p53 DNA-binding domain and could 
induce expression of p21 protein (a canonical p53 target gene) (Kaghad et 
al., 1997). Much of the initial work on p73 focused on its role in tumor 
suppression given its similarity to p53. However, mice lacking p73 (p73-/-) 
had distinct phenotypes compared to p53-/- mice, exhibiting developmental 
defects including: hippocampal dysgenesis, hydrocephalus, chronic 
infections, pheromone sensory deficits, runting, and sterility (Yang et al., 
2000). Unlike p53-/- mice, p73-/- did not exhibit an increase in spontaneous 
tumor formation (Yang et al., 2000). Only recently was a unifying 
mechanism identified to explain many of the diverse phenotypes observed 
in p73-/- mice (Marshall et al., 2016; Nemajerova et al., 2016); and the 
results leading to that mechanism will be discussed in further detail below. 
One year after the discovery of p73, a third family member, p63, was 
discovered in a screen to identify additional genes belonging to the p53 
family (Yang et al., 1998). Yang and colleagues reported that p63 had 60% 
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amino acid identity with the p53 DNA-binding domain and 85% identity with 
the p73 DNA-binding domain, and was expressed by the proliferating basal 
cells of the epithelial layers of the skin, cervix, urothelium, and prostate 
(Yang et al., 1998). The development of mice lacking p63 (p63-/-) revealed 
that p63 was essential for tissue development (Mills et al., 1999; Yang et 
al., 1999). p63-/- mice have major developmental defects including a lack 
of stratified squamous epithelia and glandular epithelial structures (hair 
follicles, sweat glands, mammary glands, prostate gland), defective limb 
and craniofacial developmental, and die shortly after birth (Mills et al., 
1999; Yang et al., 1999). Consistent with the phenotype of p63-/- mice, 
mutations in the human p63 gene (TP63) were identified as causative for 
several human ectodermal dysplasia syndromes (van Bokhoven et al., 
1999, 2001; Celli et al., 1999; Ianakiev et al., 2000; McGrath et al., 2001), 
which are characterized by the abnormal development of two or more 
ectodermal tissues (skin, hair, nails, teeth, and sweat glands) (Rinne et al., 
2007).  
These early observations led researchers to investigate the 
biological roles of p63 in epithelial development and homeostasis (versus in 
p53-like tumor suppressive functions). Subsequent studies have 
collectively shown that p63 regulates a transcriptional program that is 
essential for stem cell maintenance, proliferation, and development in 
stratified epithelial tissues (Mills et al., 1999; Senoo et al., 2007; Truong et 
al., 2006; Yang et al., 1999). In contrast with the function of p53 as a tumor 
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suppressor, elevated levels of p63 protein, resulting from p63 gene 
amplification in select tumors (Hibi et al., 2000), are oncogenic in a 
significant fraction of human squamous cell carcinomas (in the lung, head 
and neck region, and esophagus) (Hu et al., 2002; Massion et al., 2003; 
Sniezek et al., 2004; Thurfjell et al., 2005; Weber et al., 2002).  
 
Evolutionary History 
A p53 family-like gene was first observed in single cell 
choanoflagellates and early metazoans sea anemone approximately one 
billion years ago (Belyi et al., 2010). A homologue of this gene is found in 
nearly all invertebrates, where it functions in protecting germ cells from 
DNA damage and prevents genomic instability (Belyi et al., 2010). The 
three canonical p53 family genes were first observed approximately 450 
million years ago (Venkatesh et al., 2014) in early vertebrates as a result of 
two successive duplications of the ancestor p53 family-like gene (Belyi et 
al., 2010). This occurred at the time when vertebrates developed somatic 
stem cells with the capacity to maintain and repair tissues for the lifespan of 
an organism (Belyi et al., 2010). The initial gene duplication was observed 
in cartilaginous fish, yielding a p53-like gene and a p73/p63-like gene (Belyi 
et al., 2010). When bony fish diverged from cartilaginous fish shortly 
afterwards, a second gene duplication event (of the p73/p63-like gene) was 
observed, giving rise to separate p73-like and p63-like genes (Belyi et al., 
2010). The presence of these three canonical p53 family genes is 
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conserved from bony fish through most all subsequent higher vertebrates, 
including: amphibians, mammals, reptiles, and birds (Belyi et al., 2010). 
Throughout vertebrate evolution, p53 family genes took on specialized 
functions, in addition to the ancestral role of the family in maintaining 
genomic integrity of the germline, including: (1) p53 - tumor suppression in 
somatic stem cells; (2) p63 - epithelial development, differentiation, and 
stem cell maintenance; and (3) p73 - formation of multiciliated cells as well 
as neural differentiation and cell maintenance (Belyi et al., 2010; Marshall 
et al., 2016; Nemajerova et al., 2016). 
 
Gene and Protein Structure 
p53 family members have a similar gene and protein structure 
(Blandino and Dobbelstein, 2004; Yang et al., 2002). Each gene contains 
multiple promoters, that enable the generation of transcripts encoding for 
protein products with different amino (N)-terminal sequences (Figure 1.1) 
(Bourdon et al., 2005; Kaghad et al., 1997; Yang et al., 1998, 2000). 
Proteins generated from the first promoter (P1) are longer and contain a 
full-length transactivation (TA) domain, which confers a more canonical 
p53-like function at target genes (Kaghad et al., 1997; Yang et al., 1998). In 
contrast, proteins generated from the second promoter (P2) are shorter and 
have a truncated TA domain (referred to as ∆N), which typically inhibits 
canonical p53-like functions (Bourdon et al., 2005; Yang et al., 1998, 2000). 
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TAp63α
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Figure 1.1. p53 Family Gene and Isoform Structure. (A) Schematic representation of 
the full-length p53 family proteins. Protein domains are labeled with color: transactivation 
(TA), purple; DNA-binding domain (DBD), green; oligomerization domain (OD), blue; and 
sterile alpha motif (SAM) domain, red. The percentage of amino acid sequence identify 
between the domains of p53 family members are listed. (B) Schematic representation of 
the structure of p53 family genes. Known promoters and mRNA splicing isoforms are 
annotated for each gene. Exons are labeled according to the protein domain they encode 
(same schema as in A) or the type of mRNA sequence: truncated transactivation domain 
(∆N), orange; and untranslated region (UTR), gray.
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However, the ∆N proteins of p73 and p63 also bind to and activate the 
expression of specific target genes, particularly ones important in 
development (Dohn et al., 2001; Ihrie et al., 2005; Liu et al., 2004; Wu et 
al., 2003). Family member genes also undergo 3’ alternative splicing, 
producing transcripts with different 3’ exons that encode for proteins with 
different carboxy (C)-terminal sequences (Figure 1.1), resulting in variable 
ability to transactivate target genes (Bourdon et al., 2005; Kaghad et al., 
1997; Yang et al., 1998).  
Each p53 family member gene encodes a central DNA-binding 
domain with greater than 60% amino acid identify with other family 
members (63% between p53 and p73, 60% between p53 and p63, and 
87% between p73 and p63) (Yang et al., 2002). This high degree of 
sequence homology (in the DNA-binding domain) leads to structural 
conservation, resulting in the family members binding to and regulating 
overlapping target genes containing a canonical p53 consensus response 
element (Flores et al., 2002; Jost et al., 1997; Kaghad et al., 1997; Westfall 
et al., 2003) composed of two copies of RRRCWWGYYY (where R = 
purines, C = cytosine, W = adenine or thymine, G = guanine, and Y = 
pyrimidines) separated by a 0-13 bp spacer (el-Deiry et al., 1992). More 
detailed investigation of the p73 and p63 consensus DNA-binding sites 
showed that they are more degenerate than the p53 consensus site 
(Osada et al., 2005; Perez et al., 2007; Rosenbluth et al., 2011; Sasaki et 
al., 2005; Yang et al., 2010), likely reducing binding selectivity, which would 
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contribute to the differences observed in target genes (e.g. JAG1, ING1, 
and PTPN14) and biological functions between family members.  
Each p53 family gene encodes for a conserved C-terminal 
oligomerization domain (Figure 1.1) that mediates the formation of 
tetramers [consist of a dimer of dimers (Coutandin et al., 2009; Jeffrey et 
al., 1995; Joerger et al., 2009; Kitayner et al., 2006; Natan and Joerger, 
2012)], a process that increases the DNA-binding affinity and 
transcriptional activity of the transcription factor relative to monomeric or 
dimeric forms (Chène, 2001; Davison et al., 1999; Weinberg et al., 2004). 
The transcriptional activity of tetramers is also influenced by the isoforms of 
the monomers that make up each complex (e.g. generally TA isoforms are 
stronger inducers of canonical p53 target genes involved in the DNA 
damage response) (Nemajerova et al., 2018). Through the oligomerization 
domains, p73 and p63 can form heterodimers and heterotetramers with 
one another, but not with p53 (Davison et al., 1999). 
The C-terminus of full-length α isoforms of p73 and p63 contain a 
sterile alpha motif (SAM) domain that is lacking from p53 (Figure 1.1) 
(Thanos and Bowie, 1999). SAM domains are found in proteins from a 
variety of organisms, from yeast to humans, and regulate a multitude of 
biological processes through protein-protein (Kim et al., 2001; Ponting, 
1995) and protein-RNA (Aviv et al., 2003) interactions. The function of the 
p73 and p63 SAM domains are not well understood; however, early 
research linked a distinct ectodermal dysplasia syndrome [Hay-Wells or 
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ankyloblepharon-ectodermal defects-cleft lip/palate (AEC) syndrome] to 
specific mutations in the p63 SAM domain, suggesting that the domain 
might have a biological function in humans (McGrath et al., 2001). Indeed, 
Russo and colleagues found that AEC-associated mutations in the p63 
SAM domain induced protein misfolding and aggregation, unlike the p63 
mutations causative for other ectodermal dysplasia syndromes (Russo et 
al., 2018). 
 
Regulation 
Levels of p53 protein (and its transcriptional activity) are primarily 
regulated by post-translational modifications of the protein. MDM2, an E3 
ubiquitin ligase, is critical in this regulation. In unstressed cells, MDM2 
keeps cellular levels of p53 low by binding to and ubiquitinating p53, which 
marks p53 for degradation (Haupt et al., 1997). After cellular stress, p53 
and MDM2 are modified by a series of post-translational modifications 
(including phosphorylation), which prevent MDM2 from binding to and 
inhibiting p53, resulting in increased levels of p53 protein and activity 
(Shieh et al., 1997). In addition, p53 binds to and increases the expression 
of MDM2 (Barak et al., 1993), which forms an autoregulatory feedback loop 
that keeps cellular levels of p53 tightly regulated.  
The molecular details governing the regulation of p73 and p63 
protein levels and transcriptional activity are less well understood than for 
p53, but occur through a complex combination of transcriptional and post-
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transcriptional regulatory events. mRNA isoforms of p73 and p63 are 
expressed in a tissue-specific manner, suggesting that the genes are 
conditionally regulated in a cell type- and developmental-stage specific 
manner. Past studies have provided evidence to support this by identifying 
several transcription factors and signaling pathways that regulate the 
transcription of p73 and p63. E2F-1 (Irwin et al., 2000; Seelan et al., 2002; 
Stiewe and Pützer, 2000), ZEB (Fontemaggi et al., 2001), YY1 (Wu et al., 
2008), and CEBPA (Marabese et al., 2003) bind to the P1 promoter of 
TP73 and regulate expression of TAp73 mRNA. TAp73 and p53 (Grob et 
al., 2001) bind to the P2 promoter of TP73 and induce expression of ∆Np73 
mRNA. NOTCH1 activation, epithelial-to-mesenchymal transition (EMT) 
transcription factors (SNAIL, SLUG, and ZEB1), and DNA damaging agents 
repress expression of ∆Np63 mRNA (Chua et al., 2007; Herfs et al., 2010; 
Higashikawa et al., 2007; Liefer et al., 2000; Nguyen et al., 2006); while 
FGF7 and STAT3 induce expression of ∆Np63 mRNA (Cheng et al., 2009). 
LEF1/TCF/β-catenin and CEBPD bind to the P2 promoter of TP63 and 
induce expression of ∆Np63 mRNA (Barbaro et al., 2007; Borrelli et al., 
2007; Chu et al., 2008; Ferretti et al., 2011). GLI3 (Li et al., 2008) and 
OCT4 (Ng et al., 2014) induce expression of TAp63; OCT4 through binding 
to the P1 promoter of TP63. 
Similar to p53, the protein levels of p73 and p63 are regulated by 
protein-protein interactions and post-translational modifications. Proteins 
that bind to and regulate p73 and/or p63 include: (1) ITCH (E3 ubiquitin 
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ligase) that binds to and poly-ubiquitinates p73 and p63, promoting 
proteasomal degradation (Rossi et al., 2005, 2006); (2) YAP1 (Hippo 
signaling) that binds to and stabilizes p73α/β by inhibiting ITCH binding 
(Levy et al., 2007a); (3) PIRH2 (E3 ubiquitin ligase) that binds to and poly-
ubiquitinates p73 and p63, promoting proteasomal degradation (Conforti et 
al., 2013; Jung et al., 2013; Wu et al., 2011) and (4) ASPP1 and ASPP2 
that bind to p73 and p63, inducing transcriptional activity (Bergamaschi et 
al., 2004; Levy et al., 2007a) 
The coordinate regulation of target genes by p53 family members 
(Flores et al., 2002; Jost et al., 1997; Kaghad et al., 1997; Westfall et al., 
2003) occurs at multiple levels including: (1) p53 family proteins compete 
for access to the DNA-binding sites of shared target genes (DeYoung et al., 
2006; Schavolt and Pietenpol, 2007; Serber et al., 2002; Stiewe and 
Pützer, 2000); (2) regulation of p53 family isoform expression, since 
different isoforms have variable transcriptional activity at many target genes 
(Bourdon et al., 2005; Kaghad et al., 1997; Yang et al., 1998, 2000); (3) 
p53 family proteins bind to and regulate the expression of other p53 family 
members (Grob et al., 2001; Harmes et al., 2003; Westfall et al., 2003) and 
themselves (Grob et al., 2001; Li et al., 2006; Nakagawa et al., 2002); (4) 
the activity of p53 family proteins is regulated by co-binding partners 
(Dobbelstein et al., 1999; Haupt et al., 1997; Levy et al., 2007a; Rossi et 
al., 2005, 2006; Zeng et al., 1999); and (5) p73 and p63 bind to one 
another through the oligomerization domains and form transcriptionally 
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active heterotetramers (Davison et al., 1999). A recent study found that 
heterotetramers of p73 and p63 are more stable in vitro than either 
homotetramer and provided evidence for their existence in vivo through 
immunoprecipitation studies in primary keratinocytes (Gebel et al., 2016). 
This study supported a previous publication that found p73 and p63 co-
occupy DNA target sites in vivo (human ME180 cervical carcinoma cells) 
by sequential chromatin immunoprecipitation (Yang et al., 2010). The 
function of p73 and p63 heterotetramers is not well understood, but will be 
important for understanding the role of each family member in the many 
tissues (Puig et al., 2003) and cancers (DeYoung et al., 2006; Leong et al., 
2007; Rocco et al., 2006) that co-express both proteins. The complex 
regulation amongst p53 family members and of each family member 
protein by itself makes it difficult to interpret the results from any given 
study in which investigators limited their scope of study to one protein of 
the p53 family in isolation. The studies presented in Chapters III and IV 
begin to address this complexity and present results of experiments in 
which p73 and p63 are coordinately investigated at the transcript and 
protein level. 
 
Biological Roles of p73 from Knockout Mouse Models 
 p73-/- mouse models have provided significant insight to the 
biological roles of p73. Development and characterization of the first p73-/- 
mouse model was reported in 2000 (Yang et al., 2000). The model was 
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generated by deletion of exons 5 and 6 (encode for part of the DNA-binding 
domain) and each tissue in the mice was functionally deficient for all p73 
isoforms (Yang et al., 2000). The p73-/- mice exhibited developmental 
defects including: hippocampal dysgenesis, hydrocephalus, chronic 
infections and inflammation, runting, female sterility, male infertility, 
gastrointestinal bleeding, and abnormal pheromone sensory pathways 
(Yang et al., 2000). In this report and for 15 years afterwards, the diverse 
phenotypes observed in p73-/- mice lacked a clear and unifying hypothesis. 
In 2016, the Pietenpol laboratory described the generation of another p73-/- 
mouse model, through deleting exons 7-9 (encode for part of the DNA-
binding domain and the oligomerization domain), and discovered that p73 
is essential for the formation of multiciliated cells (Marshall et al., 2016). 
Many of the phenotypes observed in all the p73-/- mouse models reported 
to date can be explained by a loss of multiciliated cell function in tissues 
including: hydrocephalus - lack of multiciliated ependymal cells in the 
central nervous system to regulate cerebrospinal fluid; chronic infections - 
lack of multiciliated in the airway to clear foreign agents; female sterility - 
lack of multiciliated in the oviduct to regulate the passage of eggs from the 
ovaries to the uterus; and male sterility - sperm in the testis lack flagella). 
p73 regulates a transcriptional program in multiciliated cells that includes 
key transcriptional modulators of multiciliogenesis (e.g. Foxj1 and Myb) 
(Marshall et al., 2016; Nemajerova et al., 2016). Other studies of p73-/- 
mice have uncovered additional roles for p73 in diverse processes 
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including: survival and maintenance of cortical neurons (p73 prevents 
premature apoptosis) (Pozniak et al., 2002); neural stem cell maintenance 
(p73 promotes self-renewal and proliferation as well inhibits premature 
senescence) (Talos et al., 2010); and ovarian follicle development (p73 
regulates a transcriptional program involved in cell-to-cell adhesion and 
migration) (Santos Guasch et al., 2018).  
Isoform specific p73 knockout mouse models have been useful in 
determining the biological roles of individual p73 isoforms in development, 
homeostasis, and tumorigenesis. TAp73-/- mice, which were generated by 
deletion of exons 2 and 3 (Figure 1.1), have less severe developmental 
defects than p73-/- mice (Tomasini et al., 2008). TAp73-/- mice exhibit 
many phenotypes that overlap with p73-/- mice (but were milder) including: 
hippocampal dysgenesis, infertility, and chronic infections and inflammation 
(Tomasini et al., 2008). TAp73-/- mice develop spontaneous and 
carcinogen-induced tumors at an increased rate (not observed in p73-/- 
mice), indicating that TAp73 functions as a tumor suppressor (Tomasini et 
al., 2008), in part through binding with and modulating the activity of protein 
involved in the spindle assembly checkpoint, which promotes proper 
chromosome segregation and helps prevent aneuploidy (Tomasini et al., 
2009). Ensuing studies using TAp73-/- mice have discovered additional 
functions for TAp73 in: antioxidant defense (TAp73 protects against aging, 
premature senescence, and reactive oxygen species accumulation by 
inducing the expression of Cox4i1, a subunit of cytochrome C oxidase, the 
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final enzyme in the electron transport chain) (Rufini et al., 2012); glucose 
metabolism (TAp73 induces expression of glucose-6-phosphate 
dehydrogenase, the rate-limiting enzyme of the pentose phosphate 
pathway, which supports cell proliferation) (Du et al., 2013; Jiang et al., 
2013); spermatogenesis (TAp73 prevents the premature loss of immature 
germ cells by regulating an adhesion-related transcriptional program) 
(Holembowski et al., 2014; Inoue et al., 2014); and multiciliogenesis 
(TAp73 functions as a central regulator of multiciliated cell differentiation by 
directly activating the expression of numerous ciliary genes) (Nemajerova 
et al., 2016; Wildung et al., 2019). 
∆Np73-/- mice, which were generated by deletion of exon 3’ (Figure 
1.1), have a milder phenotype than TAp73-/- mice (Tissir et al., 2009; 
Wilhelm et al., 2010). ∆Np73-/- mice have a normal life span, are fertile, 
and lack the severe chronic infections observed in p73-/- mice (Tissir et al., 
2009; Wilhelm et al., 2010). However, both ∆Np73-/- and p73-/- mice share 
select neuronal phenotypes including hypoplasia of the cortex, choroid 
plexus, vomeronasal organ, and Cajal-Rezius cells (Tissir et al., 2009; 
Wilhelm et al., 2010). The hypoplasia observed in these p73 expressing 
neuronal cell populations is due, in part, to increased apoptosis (Tissir et 
al., 2009) and suggests a role for ∆Np73 in neuronal cell survival as a 
negative regulator of p53- and/or TAp73-dependent apoptosis. This role is 
supported by work showing that primary thymocytes from ∆Np73-/- mice 
exhibit increased apoptosis in response to DNA-damage (γ-irradiation) in a 
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p53-dependent manner (i.e. phenotype reverses in a p53-null background) 
(Wilhelm et al., 2010). 
The reduced severity or absence of phenotypes across tissue types 
in isoform-specific knockout mice (TAp73-/- and ∆Np73-/-) compared to 
global knockouts (p73-/-) (Wilhelm et al., 2010) suggest that the isoform 
classes have overlapping or interacting functions within individual tissues 
and cells. This is an important factor to consider when studying the roles of 
a p73 isoform in a given tissue in isolation. Determining which p73 isoforms 
are normally expressed in a given tissue during homeostasis is required for 
assessing the functional role of p73 in that given tissue. The expression 
pattern of p73 isoforms in normal tissues and cell types has not been well 
understood due to a lack of p73 isoform-specific antibodies and challenges 
associated with accurately quantifying RNA isoforms in genes with 
characteristics like p73, including: expression of an array of RNA isoforms 
through alternative promoter usage and alternative splicing (Figure 1.1), 
transcript length > fragment length of sequencing library, and relatively low 
expression levels (Sarantopoulou et al., 2019). We have started to address 
these challenges in the studies described in Chapters III and IV. 
During our prior study linking p73 to multiciliogenesis, we discovered 
that 50% of p63-expressing basal epithelial cells in the trachea co-express 
p73 and that tracheas from p73-/- mice exhibit a 35% reduction in the 
number of basal epithelial cells [despite the loss of the most common cell 
type (multiciliated cell) in the tissue] (Marshall et al., 2016). Co-expression 
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of p73 and p63 has been previously observed in the basal cell populations 
of other epithelial tissues (Puig et al., 2003), but little was known about the 
role of p73 in these basal progenitor cells including which isoforms they 
express. Unlike p63-/- mice (Mills et al., 1999; Yang et al., 1999), p73-/- 
mice develop stratified epithelia including the skin epidermis, indicating that 
p73 is not required for proper epidermal morphogenesis. p73 expression is 
also a marker of the basal epidermal stem cell population located near hair 
follicles (scale-like skin) (Sada et al., 2016). Numerous other studies have 
also linked p73 to stem cell activity in a variety of biological contexts 
including: neuronal stem cells (Agostini et al., 2010; Gonzalez-Cano et al., 
2010; Talos et al., 2010), induced pluripotent stem cells (Alexandrova et al., 
2013; Lin et al., 2012; Martin-Lopez et al., 2017), cancer cells (Meier et al., 
2016), and aging (Rufini et al., 2012).  
Collectively, observations from our laboratory and others, led us to 
hypothesize that p73 plays a role in the maintenance of basal epithelial 
cells and/or regulates the stem cell activity of basal progenitor cells. We 
tested this hypothesis through a series of experiments described in 
Chapters III and IV of this dissertation. To determine levels and types of 
p73 isoforms expressed by basal cells across different tissues, we 
developed an algorithm to quantify p73 isoform expression in a large-scale 
dataset of tissue-specific gene expression (53 tissues, 714 individuals, 
11,688 RNA-seq samples) (Carithers et al., 2015; GTEx Consortium, 2013) 
as described in Chapter III. In Chapter IV, we focused on a specific tissue, 
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the skin, which we discovered predominantly expresses ∆Np73 and 
analyzed p73 in relation to p63 in basal epithelial cells. We discovered that 
p73-/- mice exhibit delayed wound healing, p73 is expressed by the stem 
cell populations of the skin that govern wound healing, and that ∆Np73 
regulates the expression of a gene network involved in basal keratinocyte 
biology (Beeler et al., 2019). 
 
Epithelial Skin Biology 
 
Epidermal Differentiation and Homeostasis 
The skin functions as a barrier to protect the body from physical, 
microbial, and chemical assaults as well as unregulated loss of water and 
solutes (Proksch et al., 2008a). It has two primary layers, the epidermis and 
dermis (Figure 1.2). The epidermis is the outermost layer of the skin and is 
a stratified squamous epithelium. It consists of an inner layer of proliferative 
basal keratinocytes (connected to an underlying basement membrane) and 
outer layers of differentiating keratinocytes (Figure 1.2). The dermis is 
located beneath the epidermis, anchored to it by adhesion molecules within 
the basement membrane, and primarily composed of connective tissue that 
plays important roles in mechanical support, sensation, and 
thermoregulation. Epidermal appendages, including hair follicles and sweat 
glands as well as blood vessels that supply the epidermis, are located in 
the dermis. 
 20 
 
Figure 1.2. Schematic of Epidermal Differentiation and Markers. The epidermis is the 
outermost layer of the skin and provides most of the barrier function to the organ. It is a 
stratified squamous epithelium composed of epidermal keratinocytes organized into four 
main layers, which each have a different morphological appearance and differentiation 
status. Periodically, keratinocytes in the basal layer (progenitor population of the tissue) 
detach from the underlying basement membrane and migrate towards the surface of the 
skin while undergoing a terminal differentiation program, resulting in the production of 
dead squames that make up the stratum corneum. The expression of genes that mark 
different stages of epidermal differentiation and layers of the epidermis are shown on the 
left side of the diagram.
Granular
Layer
Stratum
Corneum
Dermis
Epidermis
Basement
Membrane
Spinous
Layer
Basal Layer
D
iff
er
en
tia
tio
n
K5
K14
Proliferating
Keratinocyte Integrins
DesmosomeAdherens
Junction
K1
K10
Loricrin
Filaggrin
Tight
Junction
Lipid
Bilayers
Cornified
Envelope
KLF4
p63
 21 
Homeostasis is generally understood as the physiological process 
that maintains the structure and function of a tissue (Stark et al., 2006). To 
achieve homeostasis, the epidermis has to maintain a constant number of 
cells through balancing of the rates of proliferation and cell loss within the 
tissue. This process is coordinated by the stem cells of the epidermis, 
which are located in the innermost basal layer. Periodically, basal cells 
detach from the underlying basement membrane and execute a terminal 
differentiation program while migrating upward toward the surface of the 
skin (Figure 1.2). In the first step of this process, keratinocytes transition 
from the basal to the suprabasal (or spinous) layer. During this transition, 
cells undergo dynamic changes in gene expression including decreased 
expression of basal keratinocyte markers (KRT5 and KRT14) and 
increased expression of spinous markers (KRT1 and KRT10) (Fuchs and 
Green, 1980). These gene expression changes result in cells with a 
network of intermediate filaments reinforced with increased numbers of 
desmosomes, which gives these cells their spinous-like appearance when 
stained with H&E (Johnson et al., 2014).  
As cells migrate upward into and through the granular layer, they 
lose their nuclei and organelles, and form keratohyalin and lamellar (lipid 
rich) granules, which gives their cytoplasm a granular appearance by H&E 
staining. In the final stages of terminal differentiation, granular cells 
undergo extensive enzymatic protein crosslinking to form the cornified 
envelope (proteinaceous sac filled with keratin filaments) and extrude their 
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lamellar granules into the extracellular space (Blanpain and Fuchs, 2009). 
The result of this process is the formation of flat and dead stratum corneum 
cells (also called squames), which provide most of the barrier function of 
the skin and are eventually shed from the surface of the skin. In humans, it 
takes approximately four weeks for basal cells to undergo this 
differentiation process and be shed from the surface of the skin (Fuchs, 
2016). 
 
Roles of p63 
p63 was established as a master regulator of epidermal 
development, differentiation, and homeostasis through the phenotypes of 
the p63-/- mouse models (Mills et al., 1999; Yang et al., 1999) and human 
diseases caused by p63 mutations (van Bokhoven et al., 1999, 2001; Celli 
et al., 1999; Ianakiev et al., 2000; McGrath et al., 2001). The findings from 
studies analyzing p63 isoform-specific knockout mouse models support 
∆Np63 being the major functional isoform in the epidermis and other 
epithelial tissues, whereas a role for TAp63 in the epidermis is disputed 
(Romano et al., 2012; Su et al., 2009; Suh et al., 2006). ∆Np63-/- mice, 
which largely phenocopy p63-/- mice, fail to develop proper stratified 
epithelia during embryonic development, indicating that ∆Np63 is essential 
for epidermal development (Romano et al., 2012). ∆Np63 is highly 
expressed by keratinocytes in the basal layer of epidermis (same cell type 
in the skin that expresses p73), the progenitor cell population of the tissue, 
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during homeostasis (Yang et al., 1998) and is essential for maintaining the 
proliferative potential of this stem cell population (Senoo et al., 2007; 
Truong et al., 2006).  
The molecular roles of ∆Np63 have been extensively investigated in 
epidermal keratinocytes. ∆Np63 binds to and regulates the expression of a 
gene expression program with important roles in biological processes of the 
epidermis such as proliferation, adhesion, differentiation, and stem cell 
maintenance (Carroll et al., 2006; Pellegrini et al., 2001; Truong et al., 
2006). Key direct p63 target genes and gene groups in these processes 
include: PERP (Ihrie et al., 2005), KRT14 (Romano et al., 2007), CDKN1A 
(p21) (Westfall et al., 2003), integrins (ITGA3, ITGA6, ITGA5, ITGB4, and 
LAMC2), CDH3 (P-cadherin) (Shimomura et al., 2008), and desmosomal 
components (DSC3, DSP, and DSG1) (Ferone et al., 2013). ∆Np63 also 
regulates gene expression in epidermal keratinocytes through modulation 
of the global chromatin structural state. SATB1 (Fessing et al., 2011) and 
BRG1 (Mardaryev et al., 2014) are p63 target genes and chromatin 
modifiers, with important roles in inducing expression of genes within the 
epidermal differentiation complex (EDC), a keratinocyte lineage-specific 
gene locus, during skin development. In addition, ∆Np63 binds to and 
regulates the chromatin state and activity of epidermal enhancers, possibly 
through acting as a pioneer factor to open compact chromatin and allow 
binding by other transcription factors (Bao et al., 2015; Kouwenhoven et al., 
2015; Rinaldi et al., 2016). 
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Given the knowledge gained from the molecular studies of ∆Np63 
function and the essential roles of ∆Np63 in epidermal cell fate 
commitment, Chen and colleagues performed a screen to identify skin 
lineage-specific transcription factors that could convert non-epithelial cells 
to the epidermal fate when co-expressed with ∆Np63 (Chen et al., 2014). 
The authors demonstrated co-expression of ∆Np63 and KLF4 could 
reprogram fibroblasts to the epidermal basal keratinocyte cell fate (Chen et 
al., 2014). In Chapter IV, we leverage the learning from this model and 
deploy it to explore the function of ∆Np73 in epidermal programming and 
discovered that ∆Np73 enhances p63-mediated expression of keratinocyte 
genes involved in skin development, proliferation, and wound healing. 
 
Wound Healing 
Following wounding, it is essential to quickly repair the epidermis 
and restore the barrier function of the skin. The wound healing process is 
generally divided into four overlapping phases: (1) blood clotting, (2) 
inflammation, (3) proliferation, and (4) remodeling (Gonzales and Fuchs, 
2017; Gurtner et al., 2008). Immediately after an injury, platelets aggregate 
in the wound and form a blood clot, which stops the bleeding and provides 
a temporary barrier. In the next phase (inflammation), resident T cells are 
activated and phagocytes (macrophages, monocytes, and neutrophils) are 
recruited to the wound to assist in clearing out dead cells and pathogens. 
During the next stage (proliferation) cells in the wound proliferate and begin 
 25 
the repair of the tissue (blood vessels, extracellular matrix, and epidermis). 
Basal keratinocytes near the wound are activated to express a 
transactional program (e.g. KRT6, KRT16) that reduces cell-cell and cell-
substrate adhesion, allowing the cells to migrate into the wound and 
participate in re-epithelialization of the epidermis (Figure 1.3) (Coulombe, 
1997). The basal keratinocytes behind the migrating epidermal front are 
also involved in re-epithelialization by undergoing proliferation (Figure 1.3) 
(Werner and Grose, 2003). In the final stage of wound healing 
(remodeling), the dermis is repaired and its collagen is remodeled to 
increase its tensile strength. 
The importance of p63 in wound healing was first exemplified by the 
healing deficits observed in patients with ectodermal dysplasias caused by 
mutations in the human TP63 gene (van Bokhoven et al., 1999, 2001; Celli 
et al., 1999; Ianakiev et al., 2000; McGrath et al., 2001). Kotster and 
colleagues went on to demonstrate a role for ∆Np63 in wound healing 
using an epidermal-specific inducible ∆Np63 knockdown mouse model 
(Koster et al., 2007, 2009). Upon induction of ∆Np63 knockdown, the mice 
developed severe skin erosions and exhibited an impaired ability to heal 
full-thickness skin wounds including a failure to undergo terminal 
differentiation (Koster et al., 2007, 2009). A study of cutaneous wound 
healing in humans reported that keratinocytes at the wound edge, migrating 
epidermal tongue, and regenerating epidermis (basal and parabasal cells) 
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Figure 1.3. Schematic of Epidermal Keratinocyte Functions During Wound 
Re-epithelialization. After cutaneous injury, basal keratinocytes near the wound edge are 
activated to express a transcriptional program (e.g. KRT6, KRT16) that results in reduced 
cell-cell and cell-substrate adhesion and a change in cellular morphology, allowing the 
cells to migrate into the wound bed and fill in the gap (cells labeled with orange nuclei). In 
addition, basal keratinocytes located behind the migrating epidermal front assist with 
re-epithelialization by undergoing proliferation (cells labeled with green nuclei). 
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express p63 (Kurokawa et al., 2006). p63 also regulates wound repair in 
human airway epithelial basal cells (Warner et al., 2013). 
Stem cells in the skin, which express ∆Np63, coordinate the wound 
healing process (Ge and Fuchs, 2018). When an injury occurs, nearby 
epidermal and hair follicle (HF) stem cells are recruited to the wound to re-
epithelialize the epidermis (Ito et al., 2005). During this process, HF stem 
cells express markers of both HF and epidermal stem cells (Ge et al., 
2017). This “mixed lineage” state is transient and resolves by the end of 
wound healing (i.e., HF stem cells in the wound adopt an epidermal stem 
cell fate) (Ge et al., 2017). In Chapter IV, we explored the functions of p73 
in epidermal wound healing and found that p73-/- mice exhibit delayed 
wound healing due in part to reduced proliferation, and that p73 is 
expressed by the cell types that govern wound healing (epidermal and hair 
follicle stem cells) (Beeler et al., 2019). 
 
Global Transcriptional Profiling 
 
Importance 
Despite having the same genotype, different cell types in the body 
have distinct phenotypes and gene expression profiles due to differential 
gene regulation. In eukaryotes, regulation of gene expression is complex 
and occurs at multiple steps including chromatin accessibility, transcription, 
RNA processing, RNA stability, translation, and protein activity. 
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Transcription factors, like the p53 family, play a key role in the regulation of 
gene expression; they bind to specific DNA sequences or other 
transcription factors and induce or repress transcription of nearby genes. 
Gene expression is commonly studied at the level of transcription (i.e., 
RNA) because it is an important step in the regulation of many genes and 
can be studied genome-wide with modern technologies. The RNA 
molecules present in a biological system reflect the genes being expressed 
at the time and can be used to infer the biological processes that are active 
in the system. Global transcriptional profiling has become a widely used 
approach in biomedical research and has provided insight into the 
transcription factors that regulate epithelial biology including: ∆Np63 
(Carroll et al., 2006; Koster et al., 2007; Kouwenhoven et al., 2015; Truong 
et al., 2006), KLF4 (Chen et al., 2003), IRF6 (Ingraham et al., 2006), 
GRHL3 (Gordon et al., 2014; Klein et al., 2017; Yu et al., 2006), FOXN1 
(Janes et al., 2004), and FOXO1 (Mori et al., 2014). We previously 
combined global transcriptional profiling with chromatin 
immunoprecipitation sequencing (ChIP-seq), a technology used to identify 
transcription factor binding-sites genome-wide, to identify genes that are 
regulated by p73 in multiciliated cells (Marshall et al., 2016). In Chapter IV, 
we used global transcriptional profiling to study the function of ∆Np73 in 
epidermal programming and discovered that ∆Np73 regulates a 
transcriptome similar to ∆Np63. 
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Development of the RNA-seq Technology 
Over the past ten years, short-read RNA-seq has supplanted 
microarrays as the preferred technology for performing global 
transcriptional profiling because of a number of advantages with the 
technology including: (1) can identify novel transcripts at a single-base 
resolution; (2) has a low background signal and a large dynamic range of 
expression; (3) can distinguish different isoforms, and (4) requires little 
input RNA (Wang et al., 2009). The laboratory-based steps in a standard 
short-read RNA-seq experiment consist of: RNA extraction, poly-A mRNA 
enrichment, cDNA synthesis, library preparation (ligation of adapters to the 
cDNA ends), and library sequencing (10-30 million times per sample). The 
Illumina platform is by far the most commonly used short-read sequencing 
technology for RNA-seq (Leinonen et al., 2011) and a typical experiment 
involves sequencing 50-150 bp from one (singe-end) or both (paired-end) 
ends of the cDNA fragments in the library. Subsequent computational steps 
include: align sequencing reads to a reference genome or transcriptome, 
quantify sequence alignments (at the gene, exon, or transcript level), and 
model differential expression. Long-read (1-50 kb) RNA-seq technologies 
(Pacific Biosciences and Oxford Nanopore) have also been developed that 
can sequence entire mRNA transcripts, but are currently not widely used 
because they have a much lower throughput and higher error rate than the 
Illumina short-read technology (Stark et al., 2019). 
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In the past five years, RNA-seq methods for studying gene 
expression in single cells (scRNA-seq) have been quickly adopted by 
investigators and undergone a rapid pace of advancement (Stark et al., 
2019). Single-cell analysis has allowed investigators to discover rare cell 
types with roles in the pathology of human diseases that would not have 
been identifiable using bulk RNA-seq, which measures the mean gene 
expression of a population of cells (Montoro et al., 2018). The workflow of 
scRNA-seq methods is built heavily on methods developed for bulk RNA-
seq and includes: isolation of single cells from samples, cell lysis, cDNA 
synthesis and tagging, PCR amplification, and Illumina sequencing. The 
recommended number of cells to sequence (published range = 10s to 
100,000s of cells) and how deeply to sequence them (typical range = 1e4-
1e6 reads per cell) in a scRNA-seq experiment vary depending on the aims 
of the experiments, the sample type, and the library preparation method 
(Hwang et al., 2018; Olsen and Baryawno, 2018). scRNA-seq data 
contains a lot of technical variance (i.e. it is noisy) and presents unique 
challenges for data analysis (Olsen and Baryawno, 2018). Novel algorithms 
and statistical methods are being actively developed to address these 
issues, but they are less mature than the methods used for bulk RNA-seq 
data analysis. Recent studies have used scRNA-seq to study cellular 
heterogeneity in the murine epidermis and hair follicle, and discovered 25 
distinct cell populations and heterogeneity within the progenitor cell 
populations of the tissue (Joost et al., 2016; Yang et al., 2017). In addition, 
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Joost and colleagues used scRNA-seq to study how skin stem cells from 
different niches respond during epidermal wounding (Joost et al., 2018). In 
Chapter IV, we leveraged these skin-related scRNA-seq datasets to 
explore p73 expression in different populations of keratinocytes in the 
murine skin, including epidermal and hair follicle stem cells. 
 
mRNA Isoform Quantification by RNA-seq 
The majority of the publicly available RNA-seq datasets were 
generated using the Illumina short-read sequencing technology (Leinonen 
et al., 2011). Short reads are typically 50-150 bp long and obtained by 
sequencing both ends of 200-500 bp cDNA fragments. A large proportion 
of mRNA transcripts are longer than 1 kb. Short-reads lack the information 
to associate differences in the sequence of mRNA isoforms (e.g. alternative 
promoter usage and splicing) that are separated by more than the length of 
the fragment (Sarantopoulou et al., 2019). As a consequence, it is difficult 
to accurately quantify full-length mRNA isoforms from short-read RNA-seq, 
particularly for genes with long transcripts and many isoforms such as p73 
and p63. 
 Quantifying the expression of p73 and p63 mRNA isoforms is 
challenging for additional reasons. mRNA isoforms of p73 and p63 have a 
long 3’ UTR (~3,500 bp for p73 and ~3,000 bp for p63), which results in: (1) 
reduced effectiveness in generating full-length cDNA during oligo(dT) 
priming due to RNA degradation and/or enzymatic errors during reverse 
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transcription, resulting in the underrepresentation of 5’ RNA sequences 
after poly-A selection and reduced sequencing coverage at the 5’ ends of 
genes (Wang et al., 2009); and (2) only a small fraction, if any, of the 
sequencing reads aligning to p73 and p63 containing information that can 
be used to analyze promoter usage and splicing. In addition, studying p73 
mRNA isoforms is particularly challenging because the gene is expressed 
at relatively low levels (<10 TPM) in cell and tissue types in which it has 
important biological functions during homeostasis (Marshall et al., 2016; 
Nemajerova et al., 2016; Santos Guasch et al., 2018). In Chapter III, we 
developed a methodology to address these challenges and used it to 
quantity the expression of the p73 and p63 isoforms. 
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CHAPTER II 
MATERIALS AND METHODS 
 
Cultured Cells 
 
Cell Culture  
CAL148 and MDA-MB-453 were grown in DMEM (Thermo Fisher Scientific, 
11965-092) with 1 µg/mL EGF and 10% FBS (Gemini Bio Products, 100-
106). HCC1806 (ATCC, CRL-2335) and HCC70 (ATCC, CRL-2315) cells 
were grown in RPMI + GlutaMAX (Thermo Fisher Scientific, 61870-036) 
with 10% FBS (Gemini Bio Products, 100-106). MCF10 (ATCC, CRL-
10317) and HMEC cells were grown as previously described (Hearnes et 
al., 2005). HaCaT (Cell Line Services, 300493), HaCaT C2 (single cell 
clone derived from parental HaCaT), HaCaT p63α-/- (lack p63α expression 
as a result of CRISPR-Cas9 genomic editing of HaCaT C2 cells), 293FT 
(Thermo Fisher Scientific, R70007), and MDA-MB-231 (ATCC, HTB-26) 
cells were grown in DMEM (Thermo Fisher Scientific, 11965-092) with 10% 
FBS (Gemini Bio Products, 100-106). Neonatal human dermal fibroblasts 
(HDFn) cells (ATCC, PCS-201-010) were grown in Medium 106 (Thermo 
Fisher Scientific, M-106-500) with 2% (v/v) Low Serum Growth Supplement 
(Thermo Fisher Scientific, S-003-10). All cell lines were grown in 100 U/mL 
Penicillin:Streptomycin (Gemini Bio Products, 400-109) and tested routinely 
for mycoplasma (Lonza, LT07-418) to ensure that all experiments were 
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performed on mycoplasma-free cultures. HDFn cells were passaged using 
ATCC Trypsin-EDTA for Primary Cells (PCS-999-003) and ATCC Trypsin 
Neutralizing Solution (PCS-999-004). All other cells were passaged using 
Thermo Fisher Scientific 0.25% Trypsin-EDTA (25200-056). 
 
Cloning Lentiviral Expression Vectors 
The coding sequences of KLF4, ∆Np63α, ∆Np73α, and ∆Np73β was 
amplified independently by PCR (while adding a restriction site to each end 
of the DNA) and cloned into pCDH-CMV-3xMCS-EF1-copGFP-T2A-puro 
by NheI (New England BioLabs, R3131S) and SalI (New England BioLabs, 
R3138S) restriction digestion and T7 DNA ligation (New England BioLabs, 
M0318S). Each expression vector was sequenced using the Sanger 
method to ensure the coding sequence matched Encyclopedia of Genes 
and Gene Variants Project (GENCODE) annotations (Frankish et al., 
2019). Further detail on all vectors including the source of the template 
DNA for each coding sequence is provided in Table 2.1. 
 
Lentivirus Production  
Lentivirus was produced in 293FT cells through transfection of second-
generation lentiviral vectors (Zufferey et al., 1997). Cells were plated in T-
175 flasks and grown to 80-90% confluency. For each lentivirus produced, 
the following vectors were diluted in 1.2 mL of Opti-MEM (Thermo Fisher 
Scientific, 31985-070): pMD2.G (1.68 pmol or 6.5 µg; Addgene, 12259), 
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Table 2.1. Vectors Used in this Dissertation. The table lists the ID, full name, and 
source of each vector.
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pxPAX2 (3.03 pmol or 21.4 µg; Addgene, 12260), and lentiviral transfer 
vector (3.83 pmol). Lipofectamine 2000 (140 µL; Thermo Fisher Scientific, 
11668500) was diluted in 1.2 mL of Opti-MEM and incubated at room 
temperature for five minutes. Diluted DNA was added to the diluted 
Lipofectamine 2000 dropwise and incubated at room temperature for 30 
minutes. Flasks of 293FT cells were switched to antibiotic-free media and 
the DNA-lipid complexes were added dropwise to the side of the flask. 
Fourteen to sixteen hours later the transfection media was removed, and 
fresh media containing antibiotics was added. Virus was harvested 48 and 
72 hours after transfection. Viral supernatant was centrifuged at 1,000 rpm 
for 5 min, passed through a 0.45 µm syringe filter (Sarstedt, 83.1826), and 
stored at -80°C. Lentivirus was titered using the Lenti-X qRT-PCR Titration 
Kit (Takara Bio). 
 
Lentiviral Infections 
Lentivirus was stored at -80°C in aliquots prior to infection and was limited 
to one freeze-thaw cycle before use. Target cells were grown to 33-66% 
confluency in 6-well or 12-well plates before infection. For every infection 
condition, equivalent copy numbers of each virus were used in the 
presence of 6 µg/mL polybrene. Each plate was spun at 2,000 rpm for one 
hour at room temperature. The spinfection procedure was repeated 24 
hours later and fresh media was added at 48 hours. Cells were grown for a 
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total of 3-6 days after the initial infection before collection and the media 
was changed every other day. 
 
Immunoblotting 
Cell pellets were collected by trypsinization and lysed in RIPA buffer 
supplemented with protease inhibitors (Sigma-Aldrich, 11697498001). 
Murine tissues were homogenized in RIPA buffer supplemented with 
protease inhibitors (Sigma-Aldrich, 11697498001) using a Diagenode 
Bioruptor with protein extraction beads (Diagenode, C20000021). The 
protein concentration of cell and tissue extracts was quantified using the 
DC Protein Assay (Bio-Rad, 500-0116). Protein samples (30-50 µg for cells 
and 100 µg for tissues) were separated on 10% SDS-PAGE gels and 
transferred to polyvinylidene fluoride (PVDF) membranes (MilliporeSigma, 
IPVH00010). Membrane blocking and antibody incubations were conducted 
in 1X TBST with 5% w/ nonfat dry milk. Primary antibody incubations were 
performed overnight at 4°C with KLF4 (R&D Systems AF3460; 1:2,000), 
p63α H-129 (Santa Cruz Biotechnology sc-8344; 1:500), p73 EP436Y 
(Abcam ab40658; 1:1,000), and GAPDH (Merck Millipore MAB374; 
1:10,000). Further detail on all primary antibodies used in immunoblotting is 
provided in Table 2.2. Secondary antibody incubations were performed 24-
26 hours later for 1 hour at room temperature using species-appropriate 
HRP-conjugated secondary antibodies (Thermo Fisher Scientific; 1:5,000). 
Membranes were incubated in ECL substrate (Thermo Fisher Scientific, 
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Table 2.2. Antibodies Used in this Dissertation. The table lists the epitope, company, 
catalog number (#), and species of each antibody, as well as dilution the antibody was 
used at in applicable applications including: immunoblotting (IB), immunofluorescence (IF), 
immunohistochemistry (IHC), and chromatin immunoprecipitation (ChIP). IF dilutions with 
an asterisk indicate that tyramide signal amplification (TSA) was used to enhance 
fluorescent signal detection. ChIP experiments were performed using 25-50 million cells. 
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32106) for 1-2 minutes and chemiluminescent signal was captured with X-
ray film or Amersham Imager 600 (GE Healthcare Life Sciences, 
29083461). 
 
RNA Isolation 
Total RNA was harvested from HDFn and MDA-MB-231 cell pellets that 
had been generated by cell trypsinization and frozen at -20°C. RNA for 
qRT-PCR analysis was isolated using the Aurum Total RNA Mini Kit (Bio-
Rad, 732-6820). Samples were treated with DNase I for 30 minutes at 
room temperature. RNA for RNA sequencing (RNA-seq) analysis was 
isolated using the RNAqueous-Micro Total RNA Isolation Kit (Thermo 
Fisher Scientific, AM1931). Samples were treated with DNase I for 20 
minutes at room temperature. All RNA samples were quantified and 
assessed for quality using a NanoDrop One Spectrophotometer (Thermo 
Fisher Scientific, ND-ONE-W). Samples for RNA-seq were also analyzed 
using the Qubit RNA assay and BioAnalyzer 2100 or TapeStation system 
(Agilent). 
 
Quantitative Reverse Transcription PCR (qRT-PCR) 
cDNA was generated from 750 ng of total RNA using MultiScribe Reverse 
Transcriptase (Thermo Fisher Scientific, 4311235) and oligo(dT) primer 
(Thermo Fisher Scientific, N8080128). Quantitative PCR was performed 
using the CXF96 Touch Real-Time PCR Detection System (BioRad, 
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1855195) with iQ SYBR Green Supermix (BioRad, 1708880). An annealing 
temperature of 60°C was used for each primer set. Samples were run in 
triplicate and normalized to GAPDH. The ∆∆Ct method was used to 
calculate relative gene expression between samples (Livak and 
Schmittgen, 2001). Primer sequences for KRT14, KRT5, FLG, SFN, and 
GAPDH are listed in Table 2.3. 
 
Human Dermal Fibroblast Induced Keratinocyte (iKC) RNA-seq 
RNA-seq was performed on HDFn cells after iKC reprogramming at the 
Vanderbilt Technologies for Advanced Genomics (VANTAGE) core. 
Stranded RNA-seq libraries were prepared from total RNA using poly-A 
enrichment and the TruSeq RNA Library Preparation Kit (Illumina). 
Libraries were sequenced on an Illumina NovaSeq 6000 or NextSeq 500 
using a paired-end 150 base pair protocol. RNA-seq reads were trimmed to 
remove adapter sequences with Flexbar v3.4.0 (Dodt et al., 2012) and 
aligned to hg19 (GRCh37 Primary Assembly) with STAR v2.6.1a (Dobin et 
al., 2013) using default parameters and GENCODE v28lift37 annotations 
(Frankish et al., 2019). The number of reads mapped to GENCODE for 
each gene was quantified with featureCounts v1.6.2 (Liao et al., 2014) and 
used with DESeq2 v1.14.1 (Love et al., 2014) to perform differential 
expression analysis between samples. Overrepresentation enrichment 
analysis was conducted on differentially expressed genes [DESeq2 false 
discovery rate (FDR) < 0.1] using WebGestaltR v0.1.1 (Wang et al., 2017). 
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Table 2.3. Primers Used in this Dissertation. The table lists the name and sequence of 
each primer used in qRT-PCR experiments. The primer pairs were designed to amplify a 
80-200 bp product and have a Tm value of ~60°C.
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Transcript abundance [units = transcripts per million (TPM)] was estimated 
using Kallisto v0.44.0 (Bray et al., 2016). FASTQ files for RNA-seq data 
from this analysis were deposited in the NCBI SRA under the BioProject ID 
PRJNA540145. 
 
Chromatin Immunoprecipitation Sequencing (ChIP-seq) 
For each p63 ChIP, 25-50 million cells were crosslinked with formaldehyde 
(1-1.5%) for ten minutes at room temperature, collected by scraping, and 
sonicated to yield approximately 300 base pair DNA fragments using a 
Diagenode Bioruptor. ChIP was performed with HaCaT and HCC1806 
using 10 µg of p63α H-129 (Santa Cruz Biotechnology, sc-8344) antibody 
or with HaCaT C2 using 10 µg of p63 (AF1916, R&D Systems) antibody. 
Input control samples were collected from sonicated samples prior to 
performing ChIP. ChIP-seq libraries were prepared as described previously 
(Marshall et al., 2016). Sequencing of ChIP-seq libraries was performed at 
the Vanderbilt VANTAGE core using the Illumina platform with a single-end 
50 or 75 base pair protocol. ChIP-seq reads were trimmed to remove 
adapter sequences using Flexbar v3.4.0 (Dodt et al., 2012) and aligned to 
hg19 (GRCh37 Primary Assembly) using BWA v0.7.17-r1188 (Li and 
Durbin, 2009) with default parameters (BWA-backtrack for 50 base pair 
reads and BWA-MEM for 75 base pair reads). Duplicate reads were 
identified using the Picard v2.17.11 tool “MarkDuplicates”. Samtools v1.9 
(Li et al., 2009) was used to filter out duplicate, multimapping, improperly 
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paired, and mitochondrial reads. Peak calling was performed with MACS2 
(Li et al., 2009; Zhang et al., 2008) using input samples as a control and a 
FDR q-value threshold of 0.01. Motif enrichment analysis was performed 
with MEME-ChIP (Machanick and Bailey, 2011) on the genomic sequences 
at detected p63 peaks (length = 500 base pair) as a QC step to ensure that 
the canonical p63/p73 DNA-binding motif was identified and the ChIP was 
successful. Analysis of p73 and p63α genomic-binding profiles in HCC1806 
cells was conducted using deepTools (Ramírez et al., 2014). p63/p73-
binding sites within 50 kb of the transcription start sites (TSS) of the set of 
44 genes involved in iKC reprogramming were determined by manually 
reviewing the MACS2-identified peaks in the Integrative Genomics Viewer 
(IGV) (Thorvaldsdóttir et al., 2013). Genes were marked as containing a 
p63/p73-binding site (in Figure 4F) if an overlapping p63/p73 ChIP-seq 
peak was detected within 50 kilobases of the TSS in two out of three basal 
cell models analyzed [HK (Kouwenhoven et al., 2015), HaCaT, and 
HCC1806 (Santos Guasch et al., 2018)] and the overlapping peak 
contained a canonical p63/p73 DNA-binding motif. FASTQ files for ChIP-
seq data generated as part of this analysis were deposited in the NCBI 
SRA under the BioProject ID PRJNA540145. Further detail on all primary 
antibodies used in the ChIP analyses is provided in Table 2.2. 
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Murine Model 
 
Animal Model 
We used the previously described p73+/+ and p73-/- mice (Marshall et al., 
2016) in a BALB/c congenic background (Santos Guasch et al., 2018) for 
all experiments requiring murine tissue. The research using mice described 
herein was carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes 
of Health (NIH). The protocol was approved by the Institutional Animal Care 
and Use Committee (IACUC) of Vanderbilt University Medical Center 
(Protocol Number: M08636). All surgery was performed under controlled-
dose isoflurane anesthesia, and all efforts were made to minimize suffering. 
 
Immunofluorescence (IF) and Immunohistochemistry (IHC) 
Immunostaining of tissue sections was performed as previously described 
(Marshall et al., 2016). Murine skin tissues were fixed in 10% neutral 
buffered formalin (NBF) and embedded in paraffin for sectioning. De-
identified human skin sections were obtained from pre-existing formalin-
fixed paraffin-embedded tissue blocks. These blocks were prepared from 
excess tissue remaining after evaluation and diagnosis at the time of a 
surgical procedure. The Vanderbilt University Medical Center Institutional 
Review Board considers these tissues exempt since they were pre-existing 
and de-identified. IF was conducted using the following antibodies: p73 
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EP436Y (Abcam ab40658; 1:1,000), p63α D2K8X (Cell Signaling 
Technology #13109; 1:1,000), Keratin 5 (Fitzgerald Industries International 
20R-CP003; 1:200), Keratin 14 (Fitzgerald Industries International 20R-
CP002; 1:200), E-cadherin (BD Biosciences 610181; 1:1,000), Keratin 10 
(Abcam ab76318; 1:100), and Ki67 B56 (BD Biosciences 550609; 1:1,000). 
p73, p63, and Ki67 were detected using TSA Plus Fluorescence 
Amplification Kit (PerkinElmer). Keratins (5, 10, 14) and E-cadherin were 
detected using species-appropriate Alexa Fluor secondary antibodies at 
1:200 (Thermo Fisher Scientific). IHC was conducted using γH2AX (Novus 
Biologicals NB100-2280; 1:1,000) antibody. Further detail on all primary 
antibodies used in immunostaining is provided in Table 2.2. 
 
Cutaneous Wounding Assay 
Mice (8-12 months old; ~1:1 ratio of males and females) were anesthetized 
using a controlled dose of isoflurane and four full-thickness wounds were 
made in the back skin using a 0.5 cm biopsy punch following Vanderbilt 
IACUC-approved protocols. Mice were monitored daily after wounding. 
Samples were collected at 0 (immediately after wounding), 3, 7, and 10 
days after wounding with a total of eight wounds from two mice collected 
per time point. During sample collection, wounds were measured with 
calipers [wound area = (length/2) x (width/2) x π] and the back skin was 
harvested, fixed overnight in 10% NBF, and paraffin-embedded for further 
analysis. Whole tissue sections were digitally acquired using an AxioScan 
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Z1 slide scanner (Carl Zeiss Canada). Automated semiquantitative scoring 
of staining in wounded and unwounded skin was performed on whole slide 
images by a pathologist who had not been informed of the study hypothesis 
using QuPath software (Bankhead et al., 2017). Wound and unwounded 
areas were manually annotated. At least two areas of skin were analyzed 
for each condition (minimum total area = 1.94 mm2) with the quantification 
algorithm to produce a semiquantitative score based on the percentage of 
stained nuclei (Ki67 IF) or the percentage of stained nuclei and staining 
intensity (p73 IF and γH2AX IHC). For the latter qualifications, H-scores 
were calculated using the following equation: H-score = 3*(% of 3+ intensity 
cells) + 2*(% of 2+ intensity cells) + 1*(% of 1+ intensity cells) (McCarty et 
al., 1985). Each selected region was visually assessed to verify correct 
performance of the quantification algorithm. 
 
Computational Analyses 
 
Genotype-Tissue Expression (GTEx) RNA-seq 
RNA-seq data for 11,688 human samples (51 normal tissue sites and 2 
primary cell lines) was downloaded from the GTEx Portal on January 1, 
2018 (V7 Release) (Carithers et al., 2015; GTEx Consortium, 2013). The 
RNA-seq libraries were generated from total RNA using the Illumina 
TruSeq RNA Library Preparation Kit (non-stranded, poly-A capture) and 
sequenced on the Illumina HiSeq 2000 or 2500 (>50 million 76 base pair 
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paired-end reads per sample). Sequencing reads were aligned to hg19 with 
STAR v2.4.2a (Dobin et al., 2013) using GENCODE v19 (Harrow et al., 
2012) annotations. Gene-level expression (units = TPM) were quantified 
using RNA-SeQC v1.1.8 (DeLuca et al., 2012) and junction read counts 
using STAR v2.4.2a (Dobin et al., 2013). For each sample, the number of 
reads spanning each TP73 and TP63 exon-exon junction were calculated, 
normalized to the counts per million (read counts / total number of aligned 
reads / 1e6), and used to determine isoform expression for the 5’-end (5’) 
and 3’-end (3’) of transcripts independently (see Figure 3.1 for an 
overview). The percentage of 5’ or alternative promoter usage isoform 
expression for both genes was determined by the relative amounts of 
normalized junction counts for exon 3 to exon 4 (E3-E4; corresponds to the 
TA isoform) versus exon 3’ to exon 4 (E3-E4; corresponds to the ∆N 
isoform). For TP73, the relative amount of exon 3a to exon 4 (E3a-E4; 
corresponds to the I3a isoform) was also incorporated into the analysis. 
The GTEx junction count quantification dataset did not contain information 
on the exon-spanning junctions corresponding to three previously identified 
5’ isoforms (Ex2p73, Ex2/3p73, ∆Np73’) (Murray-Zmijewski et al., 2006), 
suggesting they are expressed at low levels in human tissues. Junction 
counts for TP63 corresponding to exon 4 skipping (exon 3 or exon 3’ to 
exon 5) and an additional 216 base pair exon (located in the intron between 
exons 4 and 5) were detected at very low levels and thus excluded from the 
analysis (lacked tissue specific expression, expression simply correlated 
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with TP63 expression). 3’ or alternative splicing isoform expression for both 
genes was calculated in a similar manner, with slight modifications for each 
gene to account for differences in alternative splicing between them. The 
percentage of p73α + β [exon 10 to exon 11 (E10-E11)], p73γ + ε [exon 10 
to exon 12 (E10-E12)], p73ζ [exon 10 to exon 13 (E10-E13)], and p73δ 
[exon 10 to exon 14 (E10-E14)] was calculated by analyzing normalized 
exon-exon junction counts starting at exon 10 (E10). The relative 
expression of p73α versus β was determined by comparing normalized 
exon 12 to exon 13 (E12-E13; corresponds to the α isoform) versus exon 
12 to exon 14 (E12-E14; corresponds to the β isoform) junction counts. The 
percentage of p63γ [exon 10 to exon 11a (E10-E11a)] versus non-p63γ 
(E10-E11) was calculated by analyzing normalized exon-exon junction 
counts starting at E10. The percentage of p63δ [exon 11 to exon 14 (E11-
E14)] versus non-p63δ (E11-E12) expression was calculated, including 
normalization for the previously determined percentage of p63γ expression 
(multiplied relative percentages of p63δ and non-p63δ by the non-p63γ 
from the prior calculation). The percentage of p63β (E12-E14) and p63α 
(E12-E13) was calculated using the same methodology as for p63δ. 
Isoform expression for each tissue was calculated as the mean isoform 
expression for all samples belonging to a given tissue. 
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Encyclopedia of DNA Elements (ENCODE) TSS 
RAMPAGE (RNA Annotation and Mapping of Promoters for the Analysis of 
Gene Expression) (Batut and Gingeras, 2013; Batut et al., 2013) data for 
human adult and embryonic tissues with TP73 and/or TP63 expression (n = 
17) was downloaded from the ENCODE Project Portal (Davis et al., 2018) 
on July 1, 2019. TSS identified by the ENCODE RAMPAGE pipeline were 
manually reviewed in IGV (Thorvaldsdóttir et al., 2013) for each sample to 
validate that the signal for unique reads at the TP73 and TP63 genomic loci 
was consistent with TSS calls. 
 
Cell Line RNA-seq 
RNA-seq data for cell lines (MBA-MB-453, CAL148, and HaCaT) generated 
as part of previous unpublished studies in the Pietenpol laboratory was 
obtained. Total RNA had been isolated with Aurum Total RNA Mini Kit (Bio-
Rad, 732-6820). Library preparation and sequencing was performed by 
VANTAGE. RNA-seq libraries were made using the Illumina TruSeq RNA 
Library Preparation Kit (stranded, poly-A capture) and sequenced using the 
Illumina HiSeq platform (>30 million 76 base pair paired-end reads per 
sample). Sequencing reads were pooled and aligned to hg19 (GRCh37 
Primary Assembly) with STAR v2.6.1a (Dobin et al., 2013) using default 
parameters and GENCODE v28lift37 annotations (Harrow et al., 2012). 
Exon and exon-exon junction counts were quantified with FeatureCounts 
v1.6.2 (Liao et al., 2014) using the following parameters: “-F GTF -t exon -
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Q 10 -s 2 -T 8 -g gene_name -f -O -p -B -C -J -G genome.fa -a 
gencode.gtf”. Determination of TP73 and TP63 isoform expression was 
performed in the same manner described in the methods of the GTEx 
RNA-seq analysis. Transcript abundance was estimated with Kallisto 
v0.44.0 (Bray et al., 2016) and gene-level abundance was calculated as the 
sum of the TPM values for all protein-coding transcripts of a gene. 
 
Human Protein Atlas (HPA) RNA-seq 
RNA-seq transcript abundance data for 172 human samples across 37 
tissue sites was downloaded from the HPA website on August 3, 2018 
(version 18) (Uhlen et al., 2010). Transcript abundance had been estimated 
with Kallisto v0.42.4 (Bray et al., 2016) and gene-level abundance 
calculated as the sum of the TPM values for all protein-coding transcripts of 
a gene. 
 
Tabula Muris Single-Cell RNA-seq  
Single-cell RNA-seq (scRNA-seq) count data from 2,310 murine back skin 
cells was downloaded from the Tabula Muris Consortium (Tabula Muris 
Consortium et al., 2018) on May 29, 2018. RNA-seq libraries were 
prepared from individual FACS-sorted cells (Itga6+ and/or Cd34+) using 
the Smart-Seq2 protocol and sequenced on the Illumina NovaSeq 6000 
(100 base pair paired-end protocol). Sequencing reads were aligned to the 
mm10plus genome using STAR v2.5.2b (Dobin et al., 2013) and gene 
 51 
counts calculated with HTSEQ v0.6.1p1 (Anders et al., 2015). scRNA-seq 
count data was analyzed with Seurat v2.3.4 (Butler et al., 2018). Cells with 
less than 900 unique genes detected, less than 75,000 total gene counts, 
or more than 12% External RNA Controls Consortium (ERCC) RNA Control 
reads were excluded from the analysis. Expression data was log 
normalized and scaled to a mean of zero and variance of one for each 
gene. Regression analysis was performed on the gene expression data for 
each cell to account for variation due only to the total number of gene 
counts detected or the percentage of ERCC reads. Principal component 
analysis (PCA) was performed with the top 2,000 highly variable genes and 
the number of significant PCs for clustering analysis was determined using 
the JackStraw procedure and elbow plot analysis. Seurat analysis identified 
a total of seven clusters using the first 33 principal components and a 
resolution of 0.4. Two-dimensional visualization of scRNA-seq data was 
performed with UMAP (Becht et al., 2018) using the first 33 principal 
components. UMAP parameters used included: n_neighbors = 15 and 
min_dist = 0.2. The expression of skin cell type markers (e.g. Cd34, Ly6a, 
Fgf18, Krt14, Mki67, Krt10) was analyzed for each cluster and used to 
assign cluster annotations. Cells were classified as expressing Trp63 or 
Trp73 if they had a log-normalized expression greater than or equal to 0.5. 
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Hair Follicle Single-cell RNA-seq 
scRNA-seq gene expression data from 1,119 murine hair follicle cells 
(Yang et al., 2017) were downloaded from the National Center for 
Biotechnology Information (NCBI) Gene Expression Omnibus database 
(GSE90848). Sequencing reads were aligned to the mm10 using Bowtie2 
v2.2.9 (Langmead and Salzberg, 2012) and gene-level expression (TPM) 
quantified with RSEM (Li and Dewey, 2011). Cells were classified as 
expressing Trp63 or Trp73 if they had expression greater than or equal to 1 
TPM. 
 
Murine Stem Cell RNA-seq 
RNA-seq data on murine bulge HF (GSM2656733 and GSM2656734) and 
epidermal (GSM2656735 and GSM2656736) stem cells isolated by FACS 
with marker-based sorting (Ge et al., 2017) were downloaded from the 
NCBI Sequence Read Archive (SRA) on November 2, 2018 (SRP093638). 
FASTQ files were processed as described in the HDFn iKC RNA-seq 
methods section except mm10 genome and GENCODE vM17 annotations 
(Frankish et al., 2019) were used. 
 
Human Keratinocyte RNA-seq 
RNA-seq data on primary human keratinocytes grown and differentiated in 
vitro (Cavazza et al., 2016; Kouwenhoven et al., 2015) were downloaded 
from the NCBI SRA on October 24, 2018 (SRP044925 and SRP070902). 
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FASTQ files were processed as described in the HDFn iKC RNA-seq 
methods section. Differentiated samples used in the analysis were limited 
to those collected 6 or 7 days after the induction of differentiation. 
 
Statistical 
All statistical analyses and graphical representations were conducted using 
R (version 3.5.2 or 3.5.3) unless otherwise noted. The Spearman 
correlation between TP63 and TP73 expression across human tissues 
(GTEx and HPA RNA-seq datasets) and its statistical significance were 
calculated using the "cor.test" function in R. Wound closure and qRT-PCR 
expression data are presented as the mean +/- SEM. The two-way ANOVA 
test was used to compute the mean difference in percentage wound 
closure between p73+/+ and p73-/- mice over days 0, 3, 7, and 10 
(calculated with the R “aov” function using the genotype and days after 
wounding as factors). Student’s t-test was used to calculate statistical 
significance for wound closure on individual days, IF scores, IHC scores, 
and qRT-PCR expression (calculated with the R “t.test” function using the 
following parameters: two-sided, unpaired). Differences were considered 
significant when P < 0.05 and asterisks indicate: * = P < 0.05, ** = P < 0.01, 
and *** = P < 0.001. 
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CHAPTER III 
p73 AND p63 ISOFORM EXPRESSION IN HUMAN AND MURINE 
EPITHELIAL TISSUE 
 
Introduction 
The p73 and p63 knockout mouse models (global and isoform-
specific knockout of the genes) have enabled investigators to discover 
cellular and physiological contexts in which these transcription factors 
function in vivo and highlighted the distinct biological properties associated 
with the different protein isoforms encoded by a single gene (Nemajerova 
et al., 2016; Romano et al., 2012; Su et al., 2009; Wilhelm et al., 2010). 
Determining which p73 and p63 isoforms are expressed in a given cell or 
tissue model is an important step in deciphering the functional roles of the 
transcription factors overall. Unfortunately, analyzing p73 and p63 isoform 
expression is challenging, due to the lack of isoform-specific antibodies and 
the large number of potential isoforms that can be generated from each 
gene. The latter has likely contributed to the contradictory findings in past 
studies. The development of high-throughput or next-generation 
sequencing technologies and their application to global transcriptional 
profiling [RNA-sequencing (RNA-seq)], has made it possible to survey 
entire steady-state mRNA pools, including novel and known isoforms, at 
single base resolution in a high-throughput and quantitative manner (Wang 
et al., 2009). Sethi and colleagues recently clarified past contradictions in 
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p63 isoform expression by using RNA-seq datasets to perform a large-
scale analysis of p63 isoform expression in human cell lines and tissues 
with high levels of p63 expression (Sethi et al., 2015). There was an unmet 
need to perform a similar analysis for p73, given how poorly its isoform 
expression patterns in cells and tissues were understood, and that was the 
goal of the studies described in this Chapter. 
Quantifying the expression of p73 and p63 mRNA isoforms is 
challenging for a number of reasons. The p73 and p63 genes have a 
complex structure that generates multiple isoforms through 5’ alternative 
promoter usage and 3’ alternative splicing (Figure 3.1). Both genes have 
two promoters (P1 and P2), which give rise to isoforms with distinct 
functions in transcriptional regulation (Kaghad et al., 1997; Yang et al., 
1998, 2000). Isoforms transcribed from P1 contain a full-length 
transactivation (TA) domain (Kaghad et al., 1997; Yang et al., 1998), while 
isoforms transcribed from P2 contain a truncated TA domain (∆N) (Yang et 
al., 1998, 2000). The p73 and p63 genes also undergo 3’ alternatively 
splicing, which gives rise to a number of splice forms (termed α, β, γ, etc.) 
with differing transcriptional activity (Kaghad et al., 1997; Yang et al., 
1998). The long length (~2000-5000 bp) of p73 and p63 transcripts also 
complicates quantification of isoform expression (Oshlack and Wakefield, 
2009). All p73 and p63 isoforms contain a ~1,000 bp sequence in the 
middle (encoding the DNA-binding and oligomerization domains) that 
separates the variable 5’ and 3’ ends of each isoform (Figure 3.1), making 
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Figure 3.1. Exon Structure of p63 and p73 mRNA Isoforms. Schematic representation 
of the exon structure of p63 (A) and p73 (B) mRNA isoforms. This information was used to 
develop an algorithm to quantify the mRNA expression of p63 and p73 alternative 
promoter usage and splicing isoforms by analyzing RNA-seq reads that span exon-exon 
junctions. Exons are labeled with color according to the protein domain they encode or the 
type of mRNA sequence: full-length transactivation (TA), purple; truncated transactivation 
domain (∆N), orange; DNA-binding domain (DBD), green; oligomerization domain (OD), 
blue; sterile alpha motif (SAM) domain, red; and untranslated region (UTR), gray. 
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it very challenging to directly associate the variation at each end of the 
isoform by standard approaches (e.g. qRT-PCR, microarray, RNA-seq). In 
addition, p73 and p63 mRNA isoforms have a long 3’ UTR (~3,500 bp for 
p73 and ~3,000 bp for p63), which results in: (1) difficulty generating full-
length cDNA by oligo(dT) priming (standard approach in transcriptional 
studies) and a consequential reduction in coverage at the 5’ end of genes; 
and (2) only a small portion, if any, of the sequencing reads aligning to p73 
and p63 provide information to assess promoter usage and splicing. 
Studying p73 mRNA isoforms is also made challenging because the gene 
is expressed at relatively low levels (<10 TPM) in cells and tissues in which 
it has important biological functions during homeostasis (Marshall et al., 
2016; Nemajerova et al., 2016; Santos Guasch et al., 2018). 
p73 is co-expressed with p63 in the basal cell populations of many 
epithelial tissues (Puig et al., 2003), but little is known about p73 in these 
cells including which isoforms are expressed during homeostasis. We 
recently discovered that 50% of basal epithelial cells in the trachea 
(progenitor cell population) express p73 and that tracheas from p73-/- mice 
have reduced numbers (35%) of basal cells despite the loss of the most 
common cell type (multiciliated cell) in the epithelium (Marshall et al., 
2016). In addition, p73 expression is a marker of one of the two main basal 
epidermal stem cell populations (the one located near hair follicles in scale-
like skin) (Sada et al., 2016). These results collectively suggest a role for 
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p73 in basal epithelial cells and catalyzed our interest in determining which 
p73 isoforms are expressed in basal cells across different tissues. 
To determine which p73 isoforms are expressed in basal epithelial 
cell populations, we performed a large-scale analysis of p73 isoform 
expression using human tissue RNA-seq data from the GTEx Project 
(Carithers et al., 2015; GTEx Consortium et al., 2017). GTEx is an ideal 
dataset for this analysis because: (1) tissue collection, RNA isolation, 
library preparation, and sequencing were performed using rigorous 
standard operating procedures to ensure the generation of high-quality 
data; (2) it contains 11,688 samples from 714 donors across 53 non-
diseased tissue sites; and (3) RNA-seq was performed on each sample 
using a paired-end protocol and at a high depth of coverage (>50 million 
reads). We also analyzed p63 isoforms to gain insight to the relationship 
between p73 and p63 isoform expression; and the results served as a 
control, since the expression pattern of p63 isoforms in epithelial tissues is 
known (Sethi et al., 2015). In addition, we included non-epithelial tissues in 
the analysis to provide a resource for the research community. Finally, to 
overcome the challenges associated with quantifying the expression of p73 
and p63 mRNA isoforms, we developed an algorithm to analyze exon 
junction-spanning reads and independently quantify alternative promoter 
usage and splicing isoforms for p73 and p63. 
In the analysis described in this Chapter, we determined the 
expression patterns of p73 and p63 isoforms across a panel of 53 human 
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tissues. We found that expression of TP73 and TP63 was correlated across 
tissues, with most tissues expressing either both genes or neither gene. 
For both p73 and p63, the predominant alternative promoter usage isoform 
(TA versus ∆N) varied between tissues, whereas the predominant 
alternative splicing isoform was α in nearly all tissues (with the exception of 
p63γ being predominant in skeletal muscle). Epithelial tissues with basal 
cell populations (e.g. skin, esophagus, and vagina) expressed high levels 
of TP73 and TP63. These tissues almost exclusively expressed ∆Np63 
mRNA, consistent with previous studies (Sethi et al., 2015), whereas the 
expression of p73 alternative promoter usage isoforms was heterogeneous 
between tissues. We performed a series of analyses to explore the 
heterogeneous p73 alternative promoter usage isoform expression in 
epithelial tissues and provide evidence suggesting the existence of a 
previously unreported p73 transcription start site (TSS) in them. 
 
Results 
 
p73 and p63 Gene Expression in Human Tissue 
To study the expression patterns of p73 and p63 in human tissue 
during homeostasis, we analyzed RNA-seq data from the GTEx Project, an 
atlas of RNA expression from healthy human donor tissue (11,688 total 
samples) (Carithers et al., 2015; GTEx Consortium et al., 2017). We 
observed a significant correlation (rs = 0.49, p = 0.0003) between TP73 and 
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Figure 3.2. p73 and p63 Gene Expression in Human Tissue. Scatter plot of TP73 
versus TP63 mRNA expression (TPM) by human tissue type from the GTEx dataset. Mean 
expression (TPM + 0.1) for each tissue is plotted on a log2 scale with a LOESS smooth 
local regression line (gray). Correlation between TP73 and TP63 was quantified using 
Spearman’s rank correlation coefficient (rs). Tissues were divided into four groups based 
on the patterns of p73/p63 expression: (1) dual p73/p63-positive (blue dotted line); (2) 
single p73-positive (red dotted line); (3) single p63-positive (green dotted line); and (4) 
dual p73/p63-negative.
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TP63 expression (Figure 3.2). Overall, p63 mRNA was expressed at higher 
levels in tissues than p73 (Figure 3.2). We identified four patterns of 
p73/p63 expression across tissues. The majority of tissues expressed low 
levels (<2 TPM) of both TP73 and TP63 (referred to as dual p73/p63 
negative group henceforth) (Figure 3.2). The other large group of tissues 
expressed at least moderate levels (>2 TPM) of both TP73 and TP63 
(referred to as the dual p73/p63-positive group henceforth) and included 
many tissues that have abundant basal cell populations (e.g. skin, 
esophagus, vagina, prostate; Figure 3.2, blue dashed line). A small number 
of tissues preferentially expressed either TP73 (cerebellum and fallopian 
tube) or TP63 (skeletal muscle and bladder), which we refer to henceforth 
as the single p73- and p63-positive groups respectively (Figure 3.2; red 
and green dashed lines, respectively). These results indicate that TP73 and 
TP63 are differentially expressed between tissue types. 
 
p73 and p63 Protein Expression in Murine Tissue 
Our past research examining the roles of p73 was primarily 
performed in mice (Beeler et al., 2019; Marshall et al., 2016; Santos 
Guasch et al., 2018). In contrast, the GTEx Project analyzed the 
transcriptomes of human tissue. In order to determine if the p73 and p63 
tissue-specific gene expression patterns observed in GTEx (Figure 3.2) 
were similar in mice and if cell type-specific expression occurs within a 
given epithelial tissue, we analyzed p73 and p63α protein expression by 
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immunofluorescence (IF) in various epithelial tissues from wild-type mice 
including skin, tongue, esophagus, vagina, mammary gland, and trachea. 
In the tissues analyzed, p73 co-localized with p63α in the nuclei of cells 
located in regions of the epithelium where basal cell populations typically 
reside (Figure 3.3). These results are consistent with the tissue gene 
expression patterns observed in the human GTEx samples and our prior 
murine studies (Beeler et al., 2019; Marshall et al., 2016). 
In addition, we analyzed p73 and p63α protein expression by 
immunoblotting in various epithelial tissue from wild-type mice. Overall, the 
murine immunoblot data (Figure 3.4) were consistent with the human tissue 
mRNA expression from GTEx (Figure 3.2). Murine skin, tongue, 
esophagus, and vagina expressed both p73 and p63α protein, with ∆Np63α 
and ∆Np73α likely being the predominant isoforms based on the molecular 
weights of the protein ladders and human isoform controls (Figure 3.4). 
Murine bladder tissue expressed p63, but not p73 (Figure 3.4), consistent 
with it being one of only two tissues in the GTEx dataset that expressed 
only p63 (Figure 3.2). Skeletal muscle was included in the immunoblot to 
serve as a negative control for p73 and p63α protein expression. Skeletal 
muscle expresses p63, but it is an isoform of p63 (γ) (Mangiulli et al., 2009) 
that is not recognized by the antibody we used in immunoblotting. 
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mRNA Expression of p73 and p63 Alternative Promoter Usage 
Isoforms in Human Tissue 
Current methodologies to quantify full-length mRNA isoform 
expression are not accurate for genes with characteristics like p73 and p63 
(encode several isoforms, have long transcripts and lower expression 
levels) (Sarantopoulou et al., 2019). To overcome this challenge and 
determine p73 and p63 isoform expression in human tissue during 
homeostasis, we developed an algorithm to independently quantify 5’ 
alternative promoter usage and 3’ alternative splicing isoform expression 
for p73 and p63 in individual samples by analyzing exon junction-spanning 
reads from RNA-seq data (refer to Chapter II, GTEx Project RNA-seq for 
the full details). We applied our algorithm to the GTEx dataset and 
quantified the isoform expression of p73 and p63 for each sample, 
summarizing the results by the mean of each tissue. Alternative promoter 
usage isoform expression was quantified by analyzing the number of RNA-
seq reads that span the following exon-exon junctions: (1) exon 3 to 4 
(corresponds to TA isoforms); (2) exon 3’ to 4 (corresponds to ∆N 
isoforms), and (3) exon 3a to 4 (corresponds to I3a isoform, p73 specific) 
(Figure 3.1). ∆Np63 was the predominant isoform (80-100%) in most 
tissues from the dual p73/p63-positive group in Figure 3.1, which includes 
the skin, esophageal mucosa, vagina, and prostate (Table 3.1, column 6). 
Exceptions were the testis and transformed lymphocytes, which both 
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Gene EX-E4 Gene EX-E4
TPM Reads TA N TPM Reads TA N I3a
Skin (Suprapubic) 387 138.4 51,389 2 98 8.5 943 20 80 0
Skin (Leg) 473 116.6 59,324 3 97 8.8 1,122 13 87 0
Esophageal Mucosa 407 76.7 39,845 0 100 6.2 455 83 17 0
Vagina 115 72.9 9,127 1 99 6.3 72 81 19 0
Prostate 152 21.1 2,307 2 98 6.1 170 74 27 0
Ectocervix 6 42.2 232 2 98 3.4 3 68 32 0
Endocervix 5 4.3 19 20 80 3.0 9 67 33 0
Minor Salivary Gland 97 25.0 3,771 6 94 4.8 155 49 51 0
Mammary Gland 290 10.6 3,655 3 97 1.9 325 35 65 1
Transformed Lymphocytes 130 6.1 1,657 99 1 18.6 5,551 98 2 0
Testis 259 2.7 560 96 4 2.2 2,331 4 1 95
Cerebellum 173 0.14 27 59 41 13.6 1,864 97 3 0
Fallopian Tube 7 0.61 2 65 35 13.4 80 76 25 0
Skeletal Muscle 564 18.0 29,796 100 0 0.24 26 32 66 3
Bladder 11 35.0 474 0 100 0.72 4 54 27 19
Lung 427 1.1 436 38 62 2.5 1,375 65 35 0
Tibial Nerve 414 2.1 782 94 6 0.57 15 95 0 5
Spleen 162 0.20 31 64 36 1.7 274 95 5 0
Pituitary Gland 183 0.64 148 68 32 0.95 117 88 12 0
Thyroid Gland 446 0.50 218 70 30 0.88 384 94 6 0
Tibial Artery 441 0.87 465 74 26 0.24 14 94 7 0
Spinal Cord (C-1) 91 0.32 44 70 30 1.3 32 59 41 0
Hypothalamus 121 0.24 57 88 13 1.3 154 31 69 0
Hippocampus 123 0.19 40 73 27 1.4 149 46 54 0
Caudate 160 0.19 68 80 21 0.99 196 58 42 0
Amygdala 100 0.15 35 89 11 0.91 78 52 48 0
Nucleus Accumbens 147 0.11 29 73 28 0.67 99 50 50 0
Frontal Cortex 158 0.16 42 77 23 0.42 7 82 18 0
Subcutaneous Adipose 442 0.62 326 56 44 0.21 20 74 20 6
Terminal Ileum 137 0.31 55 84 16 0.48 59 100 0 0
Uterus 111 0.36 41 71 30 0.42 8 100 0 0
Ovary 133 0.19 28 64 36 0.57 18 100 0 0
Transverse Colon 274 0.19 94 78 22 0.29 75 97 3 0
Stomach 262 0.16 52 46 54 0.26 42 95 2 2
Pancreas 248 0.06 34 27 73 0.27 122 93 7 0
Liver 175 0.10 30 59 41 0.23 44 100 0 0
Whole Blood 407 0.08 42 61 39 0.22 137 97 3 0
%Tissue
TP63 TP73
%n
Table 3.1. mRNA Expression of p73 and p63 Alternative Promoter Usage Isoforms in 
Human Tissue. The table lists the number (n) of RNA-seq samples for each human tissue 
type in GTEx as well as the total gene abundance (units = TPM) and expression of 
alternative promoter isoforms for TP73 and TP63. Alternative promoter usage isoform 
expression was calculated through analysis of exon-exon junction-spanning reads (see 
Figure 3.1 for details). For both genes, the total number of exon junction-spanning reads 
corresponding to alternative promoter usage (EX-E4) and the mean percentage 
expression (rounded to nearest whole number) of each alternative promoter isoform is 
listed by tissue type. I3a (column 11) is a p73 isoform results from the use of an alternative 
TSS located between exons 3’ and 4 of TP73.
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predominantly expressed TAp63 (96% and 99% respectively) (Table 3.1, 
column 5). Among the tissues from the single p63-positive group in Figure 
3.1, skeletal muscle expressed TAp63 (100%) and the bladder expressed 
∆Np63 (100%) (Table 3.1, columns 5 and 6). TAp63 isoforms were more 
highly expressed in tissues with low levels (<1 TPM) of TP63 expression, 
except for lung, pancreas, and stomach (Table 3.1, columns 5 and 6).  
Among the tissues from the single p73-positive group in Figure 3.1, 
which all had high levels of TP73 expression (>10 TPM), TAp73 was the 
predominant isoform (cerebellum, 97%; fallopian tubes, 76%) (Table 3.1, 
column 9). Tissues from the dual p73/p63-positive group had variable p73 
alternative promoter usage isoform expression patterns (Table 3.1, 
columns 9 and 10). Most of these tissues expressed more TAp73 than 
∆Np73 and included: esophageal mucosa (83%), vagina (81%), prostate 
(74%), ectocervix (68%), endocervix (67%), and transformed lymphocytes 
(98%) (Table 3.1, column 9). In contrast, ∆Np73 had higher expression 
levels in the skin (80% to 87%) and the mammary gland (65%) (Table 3.1, 
column 10). The testis was unique in expressing high levels (95%) of a 
transcript that appears to result from the use of an alternative 
transcriptional start site (TSS) located between exons 3’ and 4 of TP73 
(Table 3.1, column 11). This testis-enriched isoform (referred to as I3a 
henceforth) was typically composed of the exon (referred to as exon 3a 
henceforth) starting at the I3a putative TSS, exon 4, and the ~750 bp of the 
intronic sequence immediately following exon 4 (Figure 3.1B). TAp73 was 
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expressed at higher levels than ∆Np73 in the testis (Table 3.1, columns 9 
and 10), consistent with the critical role for TAp73 in sperm maturation 
(Holembowski et al., 2014; Inoue et al., 2014). TAp73 was more highly 
expressed in tissue with low levels (<1 TPM) of TP73 expression, except 
for skeletal muscle, hypothalamus, and hippocampus (Table 3.1, column 
9). 
 
mRNA Expression of p73 and p63 Alternative Splicing Isoforms in 
Human Tissue 
We quantified the mRNA expression of alternative splicing isoforms 
for p73 and p63 by analyzing the number of RNA-seq reads that span exon 
junctions from exons 10 through 14 (Figure 3.1). For both TP73 and TP63, 
there was less variability in alternative splicing isoform expression as 
compared to alternative promoter usage isoform expression between tissue 
types (Tables 3.1 and 3.2). In all tissues but one, p63α was predominant 
(67-97%) alternative splicing isoform expressed (Table 3.2, column 5). 
p63β was the second highest expressed isoform in epithelial tissue with 
high (>10 TPM) TP63 expression and included: skin (19 and 21%), 
esophageal mucosa (19%), vagina (17%), prostate (11%), ectocervix 
(16%), minor salivary gland (14%), mammary gland (5%), and bladder 
(14%) (Table 3.2, column 6). Skeletal muscle expressed a high percentage 
of p63γ (85%), making it the only tissue in which p63α was not the most 
highly expressed alternative splicing isoform (Table 3.2, column 7). p63γ 
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Gene E10-EX Gene E10-EX
TPM Reads TPM Reads +
Skin (Suprapubic) 387 138.4 88,201 79 19 1 1 8.5 6,054 74 21 5 0 0
Skin (Leg) 473 116.6 99,042 78 21 0 1 8.8 8,258 75 20 4 0 0
Esophageal Mucosa 407 76.7 60,286 79 19 1 2 6.2 4,085 85 11 3 0 0
Vagina 115 72.9 13,200 82 17 1 2 6.3 1,033 79 16 5 0 0
Prostate 152 21.1 3,668 86 11 2 1 6.1 1,201 79 17 4 0 0
Ectocervix 6 42.2 365 82 16 2 0 3.4 27 87 13 0 0 0
Endocervix 5 4.3 28 97 3 0 0 3.0 16 84 9 7 0 0
Minor Salivary Gland 97 25.0 5,509 79 14 6 1 4.8 846 76 19 4 1 1
Mammary Gland 290 10.6 5,765 93 5 1 1 1.9 994 66 27 4 1 1
Transformed Lymphocytes 130 6.1 2,943 95 4 1 1 18.6 5,827 61 31 9 0 0
Testis 259 2.7 1,318 95 1 4 1 2.2 422 90 2 8 0 1
Cerebellum 173 0.14 43 81 4 15 0 13.6 2,553 80 11 8 0 0
Fallopian Tube 7 0.61 4 87 13 0 0 13.4 106 94 4 3 0 0
Skeletal Muscle 564 18.0 43,054 15 0 85 0 0.24 49 48 36 16 0 0
Bladder 11 35.0 650 86 14 0 0 0.72 9 81 19 0 0 0
Lung 427 1.1 687 85 11 3 1 2.5 1,183 72 22 6 0 0
Tibial Nerve 414 2.1 1,145 94 2 3 1 0.57 12 34 39 28 0 0
Spleen 162 0.20 45 86 9 4 2 1.7 337 72 20 8 0 0
Pituitary Gland 183 0.64 166 92 7 1 0 0.95 162 77 16 6 0 0
Thyroid Gland 446 0.50 327 84 7 8 1 0.88 213 71 22 7 0 0
Tibial Artery 441 0.87 683 79 7 14 1 0.24 38 70 25 2 0 3
Spinal Cord (C-1) 91 0.32 52 89 3 5 2 1.3 66 51 30 18 2 0
Hypothalamus 121 0.24 62 88 0 10 3 1.3 298 59 21 14 2 3
Hippocampus 123 0.19 52 79 5 16 0 1.4 329 61 23 15 1 0
Caudate 160 0.19 67 87 1 6 6 0.99 290 60 25 14 1 0
Amygdala 100 0.15 20 90 0 11 0 0.91 215 51 30 18 1 0
Nucleus Accumbens 147 0.11 38 71 7 22 0 0.67 187 62 25 13 0 0
Frontal Cortex 158 0.16 56 95 3 2 0 0.42 88 38 33 28 2 0
Subcutaneous Adipose 442 0.62 525 86 9 5 1 0.21 32 63 31 6 0 0
Terminal Ileum 137 0.31 78 82 9 9 0 0.48 50 71 24 5 0 0
Uterus 111 0.36 55 93 4 3 0 0.42 9 72 28 0 0 0
Ovary 133 0.19 43 87 7 5 0 0.57 16 57 39 4 0 0
Transverse Colon 274 0.19 135 91 4 5 0 0.29 84 76 18 6 0 0
Stomach 262 0.16 108 80 15 4 1 0.26 48 69 20 9 0 3
Pancreas 248 0.06 50 80 14 6 0 0.27 105 88 9 3 1 0
Liver 175 0.10 35 81 9 10 0 0.23 46 83 15 2 0 0
Whole Blood 407 0.08 88 67 9 24 0 0.22 157 46 45 8 1 0
TP63 TP73
nTissue % %
Table 3.2. mRNA Expression of p73 and p63 Alternative Splicing Isoforms in Human 
Tissue. The table lists the number (n) of RNA-seq samples for each human tissue type in 
GTEx as well as the total gene abundance (units = TPM) and expression of alternative 
splicing isoforms for TP73 and TP63. Alternative splicing isoform expression was 
calculated through analysis of exon-exon junction-spanning reads (see Figure 3.1 for 
details). For both genes, the total number of exon junction-spanning reads corresponding 
to alternative splicing (E10-EX) and the mean percentage expression (rounded to nearest 
whole number) of each alternative splicing isoform is listed by tissue type. The expression 
of p73γ and p73ε (column 13) are presented as the sum of the two isoforms because they 
have an exonic structure that is difficult to differentiate with our methodology.
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was expressed at much lower relative amounts (0-24%) in other tissues, 
with the highest levels of p63γ tending to occur in tissue with low levels (<1 
TPM) of TP73 expression (Table 3.2, column 7). Low levels of p63δ 
expression were detected in all tissues (Table 3.2, column 8). 
p73 exhibited greater diversity in alternative splicing isoform 
expression than p63 (Table 3.2). Across tissues with at least moderate 
levels (>2 TPM) of TP73 expression, p73α was the predominantly 
expressed alternative splicing isoform and included: skin (74 and 75%), 
esophageal mucosa (85%), vagina (79%), prostate (79%), ectocervix 
(87%), endocervix (84%), minor salivary gland (76%), transformed 
lymphocytes (61%), testis (90%), cerebellum (80%), and fallopian tubes 
(94%) (Table 3.2, column 11). Among these same tissues, p73β was the 
second highest expressed (4-31%) isoform (Table 3.2, column 12). We 
analyzed p73γ + p73ε in tandem because they have an exonic structure 
that is difficult for our methodology to differentiate (Figure 3.1). p73γ + p73ε 
was the third most expressed isoform in most tissues, with the highest 
levels observed in tissues with low levels (<1 TPM) of TP73 expression 
(Table 3.2, column 13). Minimal expression levels of p73δ and p73ζ were 
detected in all tissues (Table 3.2, columns 14 and 15). 
 
p63 Exon 8 mRNA Isoform Expression in Human Tissue 
 Through analysis of p63 isoform expression, we noted two different 
types of junction-spanning reads between exons 8 and 9. One type (E8) 
 71 
contained the full-length sequence of exon 8 (E8) while the other (E8s) 
lacked the last 12 bp of exon 8, which encode 4 amino acids located 
between the DNA-binding and oligomerization domains of p63 (Figure 3.1). 
The p63 E8s isoform was previously identified in mice (Rizzo et al., 2015), 
but little is known about its functions. Across tissues, we found that E8 was 
the predominant isoform expressed (~70%) and that E8s was expressed at 
lower levels (~30%) (Table 3.3, columns 5 and 6). Among tissues with high 
levels (>10 TPM) of TP63 expression, the percentage of E8 expression 
was consistent (63-77%) and did not appear to be expressed in a tissue-
specific manner like p63γ in skeletal muscle (Table 3.3, columns 5). 
 
Analysis of p73 Alternative Promoter Usage in Human Tissue 
 During analysis of the 5’ isoform expression of p73 (Table 3.1), we 
noted a large variation in isoform expression between epithelial tissues 
from the dual p73/p63-positive group. For instance, the skin predominantly 
expressed ∆Np73 (87 and 80%) while the esophageal mucosa 
predominantly expressed TAp73. We were intrigued by this observation 
because of the differences in the biological functions of TAp73 and ∆Np73 
and the commonalities between the two tissues including both: (1) 
consisting of a stratified squamous epithelium composed of multiple layers 
of keratinocytes; (2) expressing similar gene co-expression networks 
(identified in a prior analysis using the GTEx dataset) (Saha et al., 2017); 
(3) co-expressing p73 and p63α protein in the basal epithelial layer by IF 
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Gene EX-E9
TPM Reads E8 E8s
Skin (Suprapubic) 387 138.4 90,394 74 26
Skin (Leg) 473 116.6 104,144 77 23
Esophageal Mucosa 407 76.7 65,808 70 30
Vagina 115 72.9 13,656 67 34
Prostate 152 21.1 3,949 63 37
Ectocervix 6 42.2 344 66 34
Endocervix 5 4.3 28 83 17
Minor Salivary Gland 97 25.0 6,109 70 30
Mammary Gland 290 10.6 6,189 65 35
Transformed Lymphocytes 130 6.1 3,206 70 30
Testis 259 2.7 1,464 70 30
Cerebellum 173 0.14 53 56 44
Fallopian Tube 7 0.61 3 67 33
Skeletal Muscle 564 18.0 49,802 70 30
Bladder 11 35.0 726 63 38
Lung 427 1.1 768 73 27
Tibial Nerve 414 2.1 1,215 75 25
Spleen 162 0.20 45 66 34
Pituitary Gland 183 0.64 230 70 30
Thyroid Gland 446 0.50 375 74 26
Tibial Artery 441 0.87 793 73 27
Spinal Cord (C-1) 91 0.32 61 75 25
Hypothalamus 121 0.24 77 64 36
Hippocampus 123 0.19 58 49 51
Caudate 160 0.19 86 59 41
Amygdala 100 0.15 33 62 38
Nucleus Accumbens 147 0.11 52 69 31
Frontal Cortex 158 0.16 79 68 32
Subcutaneous Adipose 442 0.62 568 78 23
Terminal Ileum 137 0.31 97 75 25
Uterus 111 0.36 62 63 37
Ovary 133 0.19 38 78 22
Transverse Colon 274 0.19 121 70 30
Stomach 262 0.16 118 77 23
Pancreas 248 0.06 59 77 23
Liver 175 0.10 42 83 17
Whole Blood 407 0.08 87 73 27
Tissue
TP63
n %
Table 3.3. p63 Exon 8 Isoform Expression in Human Tissue. The table lists the number 
(n) of RNA-seq samples for each human tissue type in GTEx as well as the total gene 
abundance (units = TPM) and exon 8 isoform expression for TP63. Exon 8 isoform 
expression was calculated through analysis of exon-exon junction-spanning reads 
between exons 8 and 9. The total number of reads spanning exons 8 and 9 (EX-E9) and 
the mean percentage expression (rounded to nearest whole number) of each exon 8 
isoform is listed for each tissue type. E8s (column 6) is a p63 isoform that lacks the final 
12 bp of exon 8.
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(Figure 3.3); and (4) expressing one similarly-migrating immuno-reactive 
band by immunoblot that is consistent with the molecular weight of the 
∆Np73α protein control (Figure 3.4). 
 To explore the difference in p73 alternative promoter usage isoform 
expression between epithelial tissue from the dual p73/p63-positive group, 
we determined if the results presented in Table 3.1, which were generated 
by analyzing only exon-junction spanning reads, were supported by the 
total number of reads aligning to each exon associated with alternative 
promoter usage isoforms (Figure 3.1). The results of this analysis for select 
epithelial and non-epithelial tissue is presented in Figure 3.5. In each 
tissue, the relative number of log2 normalized counts for the exons that 
encode for the TA (exon 3) and ∆N (exon 3’) isoforms of p73 and p63 
(Figure 3.5) were consistent with our previous analysis using only exon 
junction-spanning reads (Table 3.1). While analyzing the exon expression 
data, we noticed that the expression level of TP73 exon 4 (E4, shared by 
all p73 isoforms) was much higher than the combined expression of exons 
3 (E3) and 3’ (E3’) in epithelial tissue (skin, esophageal mucosa, vagina, 
and prostate) (Figure 3.5, top). We did not observe a similar difference in 
the expression levels of E4 versus E3+E3’ for TP63 in these same 
epithelial tissues (Figure 3.5, top), or for either gene in non-epithelial tissue 
(transformed lymphocytes, skeletal muscle, and cerebellum) that 
predominantly express high levels (>10 TPM) of TAp63 and/or TAp73 
(Figure 3.5, bottom row). A decrease of RNA-seq coverage in the 5’ end of 
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genes in a particular tissue could result from the use of lower quality RNA 
for library preparation, due to the inability to generate full-length cDNA from 
degraded RNA transcripts during oligo(dT) priming. We did not find 
evidence that the epithelial tissue with reduced expression of TP73 E3+E3’ 
versus E4 had lower quality RNA as assessed by the RNA integrity number 
(RIN) and the post-mortem interval (time from death to tissue collection) 
(Ferreira et al., 2018). In addition, we analyzed the genomic sequence of 
TP73 E3’ to verify that it had similar “mappability scores” (measure of the 
ability to align short-reads to a sequence) as other exons in the gene. 
To explore the reduction in expression of TP73 E3+E3’ versus E4 
we observed in epithelial tissue in Figure 3.5, we quantified the difference 
in TP73 expression between the exon junctions corresponding to 
alternative promoter usage (EX-E4) and exon junctions shared by all 
isoforms (E5-E10). We calculated this metric for TP73 and TP63 in each 
tissue (Table 3.4) using the following equation: (sum of EX-E4 normalized 
expression) / (mean normalized expression of exon junctions between E5-
E10) * 100. Consistent with the results of the exon expression analysis in 
Figure 3.5, we observed a ~10-fold decrease in the expression of TP73 
alternative promoter usage exon junctions compared to junctions between 
exons 5-10 in epithelial tissue from the dual p73/p63-positive group (Table 
3.4). In the same epithelial tissue, we only observed a ~25% decrease in 
TP63 alternative promoter usage exon junction expression (mostly ∆Np63), 
an amount consistent with the degree of 3’ bias (higher sequencing 
 76 
EX-E4 / EX-E4 /
µ(E5-E10) µ(E5-E10)
Skin (Suprapubic) 387 51,389 2 98 72 943 20 80 0 13
Skin (Leg) 473 59,324 3 97 73 1,122 13 87 0 12
Esophageal Mucosa 407 39,845 0 100 78 455 83 17 0 9
Vagina 115 9,127 1 99 82 72 81 19 0 5
Prostate 152 2,307 2 98 73 170 74 27 0 12
Ectocervix 6 232 2 98 77 3 68 32 0 8
Endocervix 5 19 20 80 81 9 67 33 0 60
Minor Salivary Gland 97 3,771 6 94 80 155 49 51 0 14
Mammary Gland 290 3,655 3 97 74 325 35 65 1 29
Transformed Lymphocytes 130 1,657 99 1 71 5,551 98 2 0 80
Testis 259 560 96 4 53 2,331 4 1 95 NA
Cerebellum 173 27 59 41 68 1,864 97 3 0 64
Fallopian Tube 7 2 65 35 40 80 76 25 0 74
Skeletal Muscle 564 29,796 100 0 79 26 32 66 3 55
Bladder 11 474 0 100 82 4 54 27 19 45
Lung 427 436 38 62 75 1,375 65 35 0 81
Tibial Nerve 414 782 94 6 81 15 95 0 5 60
Spleen 162 31 64 36 82 274 95 5 0 76
Pituitary Gland 183 148 68 32 88 117 88 12 0 62
Thyroid Gland 446 218 70 30 72 384 94 6 0 138
Tibial Artery 441 465 74 26 75 14 94 7 0 31
Spinal Cord (C-1) 91 44 70 30 95 32 59 41 0 73
Hypothalamus 121 57 88 13 99 154 31 69 0 61
Hippocampus 123 40 73 27 87 149 46 54 0 61
Caudate 160 68 80 21 110 196 58 42 0 71
Amygdala 100 35 89 11 117 78 52 48 0 54
Nucleus Accumbens 147 29 73 28 87 99 50 50 0 77
Frontal Cortex 158 42 77 23 88 7 82 18 0 13
Subcutaneous Adipose 442 326 56 44 69 20 74 20 6 46
Terminal Ileum 137 55 84 16 80 59 100 0 0 68
Uterus 111 41 71 30 77 8 100 0 0 80
Ovary 133 28 64 36 67 18 100 0 0 84
Transverse Colon 274 94 78 22 108 75 97 3 0 77
Stomach 262 52 46 54 65 42 95 2 2 68
Pancreas 248 34 27 73 89 122 93 7 0 91
Liver 175 30 59 41 93 44 100 0 0 86
Whole Blood 407 42 61 39 65 137 97 3 0 70
TP73
% %EX-E4 
ReadsTA
TP63
I3aTissue n
EX-E4 
Reads N NTA
Table 3.4. Analysis of p73 Alternative Promoter Exon-Exon Junction Expression in 
Human Tissue. The table lists the number (n) of RNA-seq samples for each human tissue 
type in GTEx as well as the expression of alternative promoter isoforms for TP73 and 
TP63 (same data presented in Table 3.1). In addition, for each gene, alternative promoter 
exon-exon junction expression (EX-E4) was divided by the mean (μ) exon-exon junction 
expression of exons 5-10 (and multiplied by 100) in order to determine if the expression of 
sequences corresponding to p73 alternative promoter isoforms was reduced relative to 
sequences shared by all p73 isoforms. TP73 expression in the testis was excluded from 
this analysis because the tissue abundantly expressed a p73 isoform lacking exons 5-10.
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coverage at the 3’ ends of genes) seen in a typical high-quality RNA-seq 
experiment utilizing poly-A capture (i.e., 3’ bias will occur when poly-A 
capture is used) (Table 3.4). In addition, we observed a similar ~30% 
decrease in TP73 alternative promoter usage exon junction expression in 
tissue (cerebellum, fallopian tube, transformed lymphocytes) that express 
predominantly TAp73 at high levels (>10 TPM) (Table 3.4). In sum, these 
findings suggest that the decrease in TP73 alternative promoter usage 
exon junction expression is specific to epithelial tissue from the dual 
p73/p63-positive group and not simply due to tissue-specific 
characteristics, since a similar decrease in alternative promoter usage exon 
junction expression was not observed for TP63. 
 
Analysis of p73 TSS in Human Epithelial Tissue 
Having determined that select epithelial tissue express reduced 
levels of TP73 alternative promoter usage exons (compared to exons 
shared by all isoforms), we considered various possibilities that could lead 
to generation of this result. One possibility is the presence of an additional 
TSS in the TP73 locus located at or upstream of exon 4 that could yield a 
transcript encoding a protein similar in size and function to ∆Np73. To study 
it, we used RAMPAGE (RNA Annotation and Mapping of Promoters for the 
Analysis of Gene Expression), an RNA-seq sequencing method that can 
identify TSS at single-base resolution with a high signal-to-noise ratio 
across the genome (Batut and Gingeras, 2013). We analyzed human tissue 
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(adult and embryonic) RAMPAGE data produced by ENCODE Project, 
which included several adult tissue samples that were also analyzed by the 
GTEx Project. We identified a predicted TSS in the TP73 gene, located 
immediately upstream (~7 bp) of the 5’ end of exon 4, in multiple tissue 
types: skin (leg and suprapubic), embryonic skin, tongue, esophagus, and 
vagina (Figure 3.6). This TSS has not been previously described to our 
knowledge. Other epithelial tissue (embryonic tongue and prostate) had 
RAMPAGE reads (specifically the 5’ ends) align to the same E4 TSS, but it 
did not reach genome-wide significance (Figure 3.6). We did not find 
evidence of the E4 TSS in the testis (Figure 3.6) or tissue with low (<2 
TPM) levels of TP73 expression (embryonic skeletal muscle, embryonic 
spinal cord, embryonic frontal cortex, ovary) (data not shown). Consistent 
with our analysis of p73 alternative promoter usage isoform expression 
using GTEx RNA-seq (Table 3.1), we detected a predicted TSS at the 5’ 
end of TP73 exon 3a (Figure 3.6). Among the epithelial tissue in Figure 3.6, 
only leg skin and embryonic tongue contained a RAMPAGE-predicted TSS 
at the site of the canonical ∆Np73 TSS (5’ end of E3’), but all the other 
tissue except vagina had RAMPAGE reads aligning to the TSS (Figure 
3.6). None of epithelial tissue had a predicted TSS at the canonical TAp73 
TSS E1 (data not shown).  
 A transcript produced from the putative E4 TSS (E4p73) would 
contain a 34 bp 5’ UTR and a start codon 27 bp downstream of the 5’ end 
of exon 4. This transcript could potentially encode a ∆Np73-like protein 
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Figure 3.6. Analysis of p73 TSS in Human Epithelial Tissue. Genome browser view of 
human tissue RAMPAGE data (from ENCODE Project) at the 5’ end of the TP73 genomic 
locus. RAMPAGE identifies TSS across the genome at single-base resolution. Each track 
shows the density of RAMPAGE read 5’ ends and is auto-normalized (the scale is listed to 
the left of each track). RAMPAGE peaks (i.e. RAMPAGE TSS) were identified using the 
ENCODE peak detection methodology for RAMPAGE data and are marked with an 
asterisk.
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product with a N-terminal truncation of the first 22 amino acids (~∆2 kDa) 
(Figure 3.7). A previous study confirmed that the E4 start codon in ΔNp73α 
can initiate translation and produce the expected ∆Np73-like protein 
product using in vitro translation and cell-based overexpression studies 
(Grob et al., 2001). By immunoblot analysis, the migration of this isoform 
would be difficult to distinguish from ∆Np73; and, could help explain why 
the epithelial tissue in Figure 3.4 express a similar sized immuno-reactive 
p73 protein band. A similar finding was reported for p63. Rinne and 
colleagues discovered three patients with an AEC-like syndrome, caused 
by mutations in the exons of TP63 that encode the ∆N domain, that 
express a truncated ∆Np63 protein by translation re-initiation at the first 
methionine in exon 4 (Rinne et al., 2008). Collectively, these results provide 
preliminary evidence supporting the existence of a previously unreported 
p73 TSS in select epithelial tissue. 
 
p73 and p63 Isoform Expression in Human Epithelial Cells 
To generate further evidence supporting the existence of E4p73 
transcript and protein, we performed immunoblot and RNA-seq analyses on 
immortalized, transformed, and primary epithelial cell cultures originating 
from tissues that express p73. ∆Np63α was the predominant isoform 
detected in all cell lines analyzed (Figure 3.8A). These results were 
consistent with the corresponding RNA-seq data from HaCaT cells, which 
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found that ∆Np63 (99%) and p63α (84%) were the predominant alternative 
promoter usage and alternative splicing isoforms expressed respectively 
(Figure 3.8B). 
TAp73α was the predominant expressed isoform in transformed 
cells (CAL148 and MDA-MB-453) by immunoblotting (Figure 3.8A) and this 
matched the corresponding RNA-seq data for the cells (Figure 3.8B). By 
immunoblot, HaCaT cells had multiple immunoreactive bands for p73: (1) a 
major band that migrated between the ∆Np73α and TAp73β controls; and 
(2) a minor band that migrated similar to the TAp73α control (Figure 3.8A). 
In the RNA-seq data from HaCaT cells, 100% (5/5) of the p73 alternative 
promoter usage exon junction-spanning reads corresponded to the TAp73 
isoform and 0% to the ∆Np73 isoform (Figure 3.8B). Furthermore, we did 
not even detect any reads aligning to the TP73 exon (E3’) unique to ∆Np73 
isoforms (out of a total of 1,016 reads aligning to TP73). Also, we noted in 
HaCaT cells that the number of reads aligning to exons 3 and 3’ of TP73 
was much lower than the number aligning to exon 4 (6 + 0 versus 45 
respectively; 6/45 = 13%), similar to our observations in epithelial tissue 
from Figure 3.5. We did not observe this large of a difference in the number 
of reads aligning to TP73 exons 3 and 3’ versus 4 for MDA-MB-453 (67 + 2 
versus 145; 48%) or CAL148 (112 + 46 versus 205; 77%) cells. Finally, in 
HaCaT cells, p73α was the major (91%; 10/11 exon junction-spanning 
reads) and p73β was the minor (9%, 1/11) alternative splicing isoform 
expressed. Based on the protein and mRNA expression data from HaCaT 
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cells we can conclude that: (1) the major immunoreactive band for p73 is 
more likely to be ∆Np73α (or a ∆Np73α-like protein) than TAp73β given the 
lack of p73β expression by RNA-seq; (2) the molecular weight of the major 
immunoreactive band for p73 is consistent with size E4p73α in a previous 
study (Grob et al., 2001); and (3) the expression of E4p73α by HaCaT cells 
would help explain the differences observed in alternative promoter usage 
isoform expression at the mRNA and protein levels. 
We also analyzed p73 protein expression in primary cultures of 
human basal mammary epithelial cells (HMECs) (Hearnes et al., 2005). 
HMECs expressed one major immunoreactive band for p73 that had a 
molecular weight similar to the major p73 band in HaCaT cells.  
 
Conclusion 
To date, this study is the largest comprehensive bioinformatic 
analysis of p73 and p63 mRNA isoform expression. Given the rigorous 
standard operating procedures for tissue procurement and RNA-seq used 
by the GTEx Project (Carithers et al., 2015), the analysis presented in this 
Chapter should be a useful resource to investigators interested in tissue-
specific expression and the function of the various p73 and p63 isoforms. 
The p73 and p63 gene-level expression data from GTEx was largely 
consistent with previously published tissue-specific gene expression 
analyses (Di Como et al., 2002; Grespi et al., 2012; Puig et al., 2003; Sethi 
et al., 2015; Yang et al., 1998). In addition, the human tissue expression 
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data were consistent with many of the reported phenotypes observed in 
p73- and p63-deficient mice (Holembowski et al., 2014; Marshall et al., 
2016; Mills et al., 1999; Nemajerova et al., 2016; Yang et al., 1999, 2000). 
For both p73 and p63, alternative promoter usage isoform expression had 
a larger range of variation between tissues than alternative splicing isoform 
expression. Outside of p63γ expression in skeletal muscle, we observed 
little evidence for tissue-specific expression of the alternative splicing 
isoforms of p73 and p63. Nearly all tissues expressed predominantly α 
isoforms, with minor amounts of β +/- γ isoforms, and little of any other 
isoform. 
 Most human tissues that express high levels of p73 and/or p63 have 
an observable phenotype in the respective tissues of the corresponding 
knockout mouse models. We identified several tissues in our study that 
were an exception to this and had interesting isoform expression patterns. 
The adult cerebellum expressed high levels of TAp73α. Previous studies 
have determined that the cerebellum of p73-/- mice have a normal gross 
morphology (Pozniak et al., 2002) and that multiple subtypes of 
medulloblastoma, a cancer that arises from arises from cerebellar 
progenitor cells, are driven by overexpression of TAp73α (Niklison-Chirou 
et al., 2017). In these tumors, TAp73α overexpression is reported to 
support mitochondrial respiration by regulating the expression of genes 
involved in glutamine metabolism (e.g. GLS2) (Niklison-Chirou et al., 2017). 
Future studies to determine which cell types in the cerebellum express p73 
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and if p73-/- mice exhibit cerebellar phenotypes would be helpful. In 
addition, the high levels of TAp63γ expression in skeletal muscle stood out, 
because it was the only example of a tissue in which p73α and p63α was 
not the predominant isoform expressed. The role of TAp63γ in skeletal 
muscle is unknown, but a prior study determined that p63 has a 
cytoplasmic staining pattern in skeletal muscle and localizes to the Z bands 
of sarcomeres (Martin et al., 2011). It would be interesting to analyze 
embryonic skeletal muscle from p63-/- mice to determine if there are any 
gross morphological defects. 
Our study provided preliminary evidence supporting the existence of 
a previously unreported p73 TSS in multiple epithelial tissue. Further 
studies using alternative methods for identifying TSS are needed to 
establish whether or not the TSS exists in vivo. If confirmed, it will be 
important to determine the relative expression level and biological 
differences between ∆Np73 and E4p73 in physiologically-relevant contexts. 
In this Chapter, we determined the p73 mRNA isoforms expressed in 
epithelial tissues with basal cell populations. We made pragmatic use of 
this knowledge in the selection of one tissue, the skin, to serve as a model 
for the experimental results and discoveries presented in Chapter IV. 
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CHAPTER IV 
p73 REGULATES EPIDERMAL WOUND HEALING AND INDUCED 
KERATINOCYTE PROGRAMMING 
 
Introduction 
The p53 family of transcription factors (p53, p63, and p73) play 
critical roles in cell cycle regulation, DNA damage response, and cellular 
differentiation (el-Deiry et al., 1993; Kaghad et al., 1997; Marshall et al., 
2016; Mills et al., 1999; Nemajerova et al., 2016; Osada et al., 1998; 
Westfall et al., 2003; Yang et al., 1998, 1999). All three family members 
share structural and functional homology in their transactivation (TA), DNA-
binding, and oligomerization domains (Yang et al., 2002). Due to the high 
degree of sequence homology in their DNA-binding domains, family 
members bind to similar genomic regions and regulate overlapping target 
genes. Both p73 and p63 have two distinct promoters that encode for either 
a longer (TA) or shorter (∆N) transactivation domain (Kaghad et al., 1997; 
Yang et al., 1998). In general, TA isoforms induce canonical p53 activity 
(e.g. cell cycle arrest, DNA repair, and apoptosis) while ∆N isoforms can 
repress these activities by acting in a dominant-negative manner towards 
TA isoforms (Grob et al., 2001; Yang et al., 1998). ∆N isoforms can also 
induce the expression of specific target genes on their own (Ihrie et al., 
2005; Liu et al., 2004; Wu et al., 2003). Adding further complexity, both TA 
and ∆N isoforms can be alternatively spliced in their C-terminus to produce 
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variants (e.g. α, β, γ) with differing transcriptional activity (De Laurenzi et 
al., 1998; Yang et al., 1998). In addition to sharing overlapping target 
genes, p73 and p63 isoforms can form stable heterodimers through 
association of their oligomerization domains (Davison et al., 1999; Joerger 
et al., 2009).  
The complicated interplay between p73 and p63 proteins has made 
studying the individual roles of each protein challenging. The development 
of knockout mouse models has provided insight to the distinct biological 
roles of p63 and p73. Mice lacking p63 (p63-/-) fail to develop stratified 
epithelia, epithelial appendages, and limbs; and die shortly after birth due 
to desiccation (Mills et al., 1999; Yang et al., 1999). Studies have 
collectively shown that p63 (specifically ∆Np63α) is expressed in basal 
progenitor cell populations of ectodermal tissues and is essential for stem 
cell maintenance, proliferation, and development (Mills et al., 1999; Senoo 
et al., 2007; Truong et al., 2006; Yang et al., 1999). Mice lacking p73 (p73-
/-) have a diverse set of phenotypes including hydrocephalus, hippocampal 
dysgenesis, sterility, chronic infections, and premature aging (Marshall et 
al., 2016; Nemajerova et al., 2016; Rufini et al., 2012; Santos Guasch et 
al., 2018; Yang et al., 2000). Many of these phenotypes are primarily due to 
the loss of multiciliated cells, which require a TAp73-mediated 
transcriptional program to develop. We previously reported that 50% of 
p63-expressing basal epithelial cells in the trachea co-express p73 and that 
tracheas from p73-/- mice exhibit a 35% reduction in the number of basal 
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epithelial cells (Marshall et al., 2016). However, the role of p73 in basal 
progenitor cells is largely unknown. Studies of somatic cell reprogramming 
have provided clues by showing that p73 is required for effective 
generation of induced pluripotent stem cells (iPSCs) with Yamanaka factors 
(Lin et al., 2012; Martin-Lopez et al., 2017). Mouse embryonic fibroblasts 
lacking p73 have impaired mesenchymal-to-epithelial transition (a rate-
limiting step during reprogramming), resulting in iPSCs with a defective 
epithelial phenotype (Martin-Lopez et al., 2017). 
The skin has proven to be an excellent model system for studying 
basal cell function during homeostasis and after injury (e.g. wounding). The 
skin forms a barrier that protects the body from physical, microbial, and 
chemical assaults as well as unregulated loss of water and solutes 
(Proksch et al., 2008b). The epidermis [also referred to herein as the 
interfollicular epidermis (IFE)] is the primary component of the skin barrier 
and consists of a multi-layered stratified epithelium with appendages. Basal 
stem cells in the innermost layer of the epidermis are essential for 
maintaining tissue homeostasis and give rise to cells that detach from the 
basal layer, exit the cell cycle, and undergo a differentiation program. 
During this process, keratinocytes migrate towards the surface of the skin 
and undergo a tightly controlled series of gene expression changes that 
result in the production of dead squames, which are essential for 
maintaining the skin barrier (Blanpain and Fuchs, 2009). Following 
wounding, it is essential to quickly repair the epidermis and restore the 
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barrier function of the skin. Stem cells of the skin, located in the basal layer 
of the epidermis and the hair follicle (HF) bulge, regulate this process (Ge 
and Fuchs, 2018). Stem cells near the wound are activated to migrate into 
the wound bed and proliferate, helping reepithelialize the wound epidermis 
(Ito et al., 2005; Levy et al., 2007b). 
We used the skin as a model system to investigate the role of p73 in 
basal epithelial cells and discovered that p73 is required for timely healing 
of cutaneous wounds. Wounds in p73-/- mice healed slower and 
demonstrated decreased proliferation and increased levels of biomarkers 
associated with the DNA damage response in basal keratinocytes at the 
epidermal wound edge. In addition, p73 expression increased in the basal 
keratinocytes at the wound edge of p73+/+ mice. Through analysis of 
single-cell transcriptomic data, we found that p73 was expressed by 
epidermal and HF stem cells, the cell types that regulate wound healing. 
Using a model of somatic cell reprogramming, we determined that ∆Np73 
enhances the expression of keratinocyte genes involved in skin 
development, proliferation, and wound healing. 
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Results 
 
Analysis of p73 Expression in Human and Murine Skin 
To determine which tissues express p73, we analyzed 
transcriptomic data from 37 human tissues (Uhlen et al., 2010). We 
observed expression [>1 transcript per million (TPM)] of TP73 in many 
tissues with basal cell populations, including: skin, esophagus, prostate, 
tonsil, salivary gland, and lung (Figure 4.1). Across all tissues, expression 
of TP73 was significantly (p = 0.0003) correlated with expression of TP63 
(Figure 4.1), a marker of basal epithelial cells. Given that TP73 and TP63 
co-expression was highest in the skin, there are robust model systems for 
studying this organ, and we previously determined which p73 isoforms are 
expressed in this tissue (Chapter III, Tables 3.1 and 3.2), we focused our 
analysis on the role of p73 in the skin and its interplay with p63. 
Prior work from our laboratory has shown that some pan-p73 
antibodies cross-react with p63 (Rosenbluth et al., 2009). In order to 
validate that the pan-p73 antibody (EP436Y) used in our studies did not 
cross-react with p63 and confound our results, we conducted immunoblot 
analyses on a diverse set of primary and transformed human epithelial cells 
using p73 (EP436Y), p63 (AF1916), and p63α (H-129) antibodies (Figure 
4.2). Cells selected for analysis expressed varying levels of p73 and p63 
mRNA in public databases and included a triple-negative breast cancer cell 
line that did not express either p73 or p63 mRNA (HCC70). We found that 
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Figure 4.1. p73 and p63 Gene Expression in Human Tissue. Scatter plot of TP63 
versus TP73 RNA-seq expression (units = TPM) by human tissue type (n = 37) from the 
Human Protein Atlas (172 total samples). Mean expression (TPM + 0.1) for each tissue is 
plotted on a log2 scale with a LOESS smooth local regression line (gray). Correlation 
between TP63 and TP73 was quantified using Spearman’s rank correlation coefficient (rs).
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p73 EP436Y recognized all four human p73 isoform controls, detected 
protein expression levels consistent with the known p73 and p63 mRNA 
levels, lacked non-specific detection in cells (HCC70) that do not express 
p73 RNA, and did not cross-react with p63 (Figure 4.2). These results 
validate the specificity of p73 EP436Y and are consistent with previous 
reports of the antibody’s specificity in immunofluorescence (IF) analyses 
(Marshall et al., 2016; Santos Guasch et al., 2018). 
We performed IF staining for p73 and p63α on human and murine 
skin to determine cell expression patterns (Figure 4.3A). In both species, 
p73 expression was nuclear and limited to a subset of p63-positive cells in 
the IFE, outer root sheath (ORS) of the HF, hair bulb, and sebaceous gland 
(Figure 4.3A). We did not detect p73 expression in the hair shaft (HS) or 
the suprabasal layer of the IFE. Both species expressed p73 in the basal 
layer of the IFE, but expression in the suprabasal layer was primarily 
limited to human skin (Figure 4.3A). In human skin, p73 was strongly co-
expressed with p63α in the stem cell compartment of the HF, termed the 
bulge (Figure 4.3A, top panel). The bulge is a specific area of the ORS 
containing HF stem cells that is located between the attachment site of the 
arrector pili muscle and the opening of the sebaceous gland (Cotsarelis et 
al., 1990). We also saw expression of p73 in the bulge region of murine 
HFs. IF staining for p73 and p63α in murine skin (Figure 4.3A, bottom 
panel) was consistent with immunoblot analysis of the tissue (Figure 4.3B). 
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The IF results indicate that p73 expression in the skin is limited to a subset 
of p63-positive basal cells in the IFE and HF, and imply a role for p73 in 
basal keratinocytes. 
 
p73 is Co-expressed with p63 Throughout Murine Embryonic Skin 
Development 
To determine if p73 is co-expressed with p63 during skin 
development in a pattern similar to that of adult murine tissue (Figure 4.3A, 
bottom panel), we performed IF staining for p73 and p63α in murine skin at 
several time points during embryogenesis. Similar to adult mice (Figure 
4.3A, bottom panel), p73 was coordinately expressed with p63α in basal 
cells at all developmental time points analyzed (Figure 4.4). During early 
embryonic stages (E12.5 and E13.5), p73 was expressed at low levels in 
the single-layered epidermis. At later time points during epidermal 
stratification (E14.5 and E16.5), expression of p73 increased and was 
restricted to cells in the basal layer, while p63α was expressed in both the 
basal and suprabasal layers (Figure 4.4). HF morphogenesis is the process 
in which specific subsets of basal cells within the epidermis divide 
perpendicularly to the basement membrane and grow downward into the 
dermis to form HFs. p73 was highly expressed during HF morphogenesis 
(E16.5-P1) in the ORS and hair bulb of developing HFs (Figure 4.4). By 
postnatal day 1 (P1), p73 expression in the basal IFE was reduced and 
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limited to only a subset of cells (Figure 4.4), similar to the IF staining seen 
in adult mice (Figure 4.3A, bottom panel). 
 
p73-/- Murine Skin has a Normal Morphological Appearance 
To evaluate if p73 plays a role in skin morphogenesis, we analyzed 
the skin of p73-/- mice (Marshall et al., 2016; Santos Guasch et al., 2018). 
Analysis of H&E-stained tissues showed no overt morphological differences 
between the back skin of adult p73+/+ and p73-/- mice (Figure 4.5A). 
Likewise, IF staining for markers of epidermal differentiation (K5, p63α, 
K14, E-cadherin, and K10) in p73+/+ and p73-/- mice demonstrated no 
significant difference in expression or localization (Figures 4.5B-E). HFs in 
Figure 4.5 that appear disconnected from the epidermis represent an 
artifact of sectioning. These results suggest that p73 is not required for 
proper epidermal morphogenesis or differentiation in mice. 
 
p73-/- Mice Exhibit Delayed Wound Healing 
Given the lack of phenotypic differences in the skin of p73-/- mice 
under homeostatic conditions and the importance of basal keratinocytes, 
which express p73, in wound healing, we examined the role of p73 in the 
skin after epidermal wounding. We generated full-thickness wounds 
(diameter = 0.5 mm) on the backs of adult p73+/+ and p73-/- mice and 
analyzed the wound-healing process at post-wound days 0, 3, 7, and 10. 
Over the 10-day time course, the rate of wound closure was significantly 
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(p = 0.004) decreased in p73-/- mice compared with p73+/+ mice, with the 
largest difference (p = 0.0125) occurring on post-wound day 7 (Figure 4.6). 
To gain insight to the molecular processes underlying the wound 
healing defect in p73-/- mice, we conducted IF and immunohistochemistry 
(IHC) staining on wounded skin sections from p73+/+ and p73-/- mice at 
post-wound days 3, 7, and 10. Semiquantitative scores of staining were 
generated by a pathologist using QuPath software (Bankhead et al., 2017) 
and reflect both the percentage of stained nuclei and staining intensity. In 
p73+/+ mice, p73 IF staining was increased in wounded compared to 
unwounded skin, and this difference was largest (p = 0.00007) at post-
wound day 7 (Figure 4.7A). The increase of p73 expression after wounding 
was primarily due to increased expression in basal keratinocytes at the 
epidermal wound edge and in the newly-formed wound epidermis (Figure 
4.7B). These periwound basal keratinocytes had a diffuse and continuous 
p73 expression pattern, in contrast with the intermittent p73 expression 
detected in basal keratinocytes of unwounded skin (Figures 4.7B). Adjacent 
normal (non-wounded) epidermis had less p73 IF staining than the 
epidermal wound edge (Figure 4.8) and overall had a similar staining 
pattern as unwounded skin (Figure 4.7B). 
Timely wound healing is dependent on a rapid proliferation response 
by basal keratinocytes at the epidermal wound edge. We found that 
expression of Ki67, a marker of proliferation, was increased in the skin after 
wounding by IF for both genotypes (Figure 4.9A). The increase of Ki67 
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expression in wounded skin was localized to the epidermal wound edge, 
adjacent HFs, and newly-formed wound epidermis (Figure 4.9B). At post-
wound day 3, we detected a significant decrease (p = 0.00003) in the 
percentage of Ki67-positive cells in the skin of p73-/- compared to p73+/+ 
mice (Figures 4.9A and B), consistent with the observation that the largest 
difference in wound closure between the two genotypes occurred at post-
wound day 7 (Figure 4.6). The reduction of Ki67 staining in p73-/- wounds 
at post-wound day 3 was primarily due to decreased staining in the basal 
keratinocytes at the epidermal wound edge and in the newly-formed wound 
epidermis, and, to a lesser extent, adjacent HFs (Figure 4.9B). We did not 
detect a difference in Ki67 expression between the unwounded skin of 
p73+/+ and p73-/- mice (Figures 4.9A and B). 
Previous work has shown that DNA damage contributes to the 
decline in stem cell function in aged tissues (Oh et al., 2014) and that p73 
regulates the response to DNA damage (Flores et al., 2002; Tomasini et 
al., 2008; Wilhelm et al., 2010). γH2AX is a marker of the DNA damage 
response and replication stress (Rogakou et al., 1998; Ward and Chen, 
2001). In both p73+/+ and p73-/- mice, levels of γH2AX in the skin 
increased after wounding by IHC (Figures 4.10A and B). The increase of 
γH2AX staining was detected in the epidermal wound edge, adjacent HFs, 
and newly-formed wound epidermis (Figure 4.10B). We observed a 
significant increase (p = 0.007) of γH2AX levels in p73-/- versus p73+/+ 
wounds at post-wound day 10 (Figures 4.10A and B). Collectively, these 
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data establish a role for p73 in epidermal wound healing, in part through 
regulation of proliferation and the DNA damage response in basal 
keratinocytes. 
 
 p73 is Expressed by Epidermal and Hair Follicle Stem Cells 
 Epidermal and HF stem cells regulate tissue homeostasis and 
wound healing in the skin (Ge and Fuchs, 2018). After epidermal injury, 
both epidermal and HF stem cells contribute to the wound-healing process 
by undergoing local migration and proliferation to ensure rapid repair of the 
epidermis and reestablishment of the skin barrier (Ito et al., 2005). Based 
on the observation that the expression pattern of p73 overlaps with regions 
of the skin where the stem cell populations reside (Figure 4.3A) and that 
p73-/- mice have delayed epidermal wound healing (Figure 4.6) due in part 
to decreased basal keratinocyte proliferation (Figure 4.9A), we determined 
p73 expression in epidermal and HF stem cells using transcriptomic data 
sets. We analyzed single-cell RNA-seq (scRNA-seq) data from 2,310 
murine back skin cells (Tabula Muris Consortium et al., 2018) that were 
isolated by Itga6 (skin epithelial integrin) and/or Cd34 (bulge HF stem cell 
marker) expression using fluorescence-activated cell sorting (FACS). 
Cluster analysis was performed with Seurat (Butler et al., 2018) and 
identified seven distinct cell clusters. We visualized the data using uniform 
manifold approximation and projection (UMAP) (Becht et al., 2018), a 
nonlinear dimensionality reduction technique that preserves both local and 
 108 
 109 
global data structure (Figure 4.11A). Cells were separated along UMAP1 
based on their region of origin within the skin, either HF bulge (Cd34+) or 
IFE (Ly6a+) (Figures 4.11A and B). HF bulge cells were divided into two 
clusters, one that expressed outer bulge markers (cluster #1, e.g. Krt24) 
and another that expressed inner bulge markers (cluster #2, e.g. Fgf18) 
(Figures 4.11A and B) (Joost et al., 2016). IFE cells were divided between 
five clusters (Figures 4.11A and B). Cluster #7 was distinguished by the 
expression of the differentiation markers Krt1 and Krt10 (Figure 4.11B). 
The remaining IFE clusters all expressed basal cell markers (e.g. Krt14 and 
Itga3) (Figure 4.11B). Among these, cluster #3 was characterized by stem 
markers (e.g. Sox9) and cluster #4 by proliferation markers (e.g. Mki67 and 
Top2a) (Figure 4.11B). Clusters #5 and #6 lacked distinguishing cell type 
markers (Figure 4.11B), but cluster #5 was unique in being the only cluster 
composed almost exclusively of cells from one stage (telogen) of the hair 
cycle. 
 We determined if each skin cell expressed Trp73 and Trp63 and 
summarized the results by cluster number (Figure 4.11C). Most (>85%) 
cells that expressed Trp73 also expressed Trp63 (Figure 4.11C). The 
percentage of cells with Trp73 expression (p73+/p63- and p73+/p63+) was 
highest in the outer bulge cluster (Figure 4.11C), the stem cell 
compartment of the HF (Cotsarelis et al., 1990). Trp73 was expressed by a 
subset of cells in all of the basal IFE clusters (Figure 4.11C), the stem cell 
compartment of the epidermis. The basal proliferating IFE cluster had the 
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second-highest percentage of cells that expressed Trp73 (Figure 4.11C), 
consistent with a prior study that found increased expression of Trp73 by 
non-label-retaining keratinocytes (i.e. those that divide more frequently) of 
the murine IFE (Sada et al., 2016). The inner bulge and differentiating IFE 
clusters did not express Trp73 (Figure 4.11C). Trp73 was expressed in a 
lower percentage of cells within each cluster than Trp63 (Figure 4.11C), 
consistent with its lower expression levels in the tissue (Figure 4.1). Trp63 
was expressed by greater than 90% of cells in each cluster (p73-/p63+ and 
p73+/p63+) except for the inner bulge (Figure 4.11C).  
Given that the outer bulge cluster had the highest percentage of 
cells that expressed p73 and p63 (Figure 4.11C), we decided to further 
study Trp73 expression in defined HF stem cell populations. To do so, we 
analyzed an additional scRNA-seq dataset (Yang et al., 2017) that profiled 
diverse types of murine HF stem cells at different stages of the hair cycle. 
In telogen (quiescent stage), a large percentage of bulge HF stem cells and 
hair germ cells (56.4% and 59.2% respectively) expressed Trp73 (Figure 
4.12). During the transition from telogen to anagen I, hair germ cells are 
activated to proliferate (Greco et al., 2009); a large percentage of these 
cells (59.6%) retained expression of Trp73 (Figure 4.12). As anagen 
proceeds, the hair germ gives rise to transit-amplifying cells, which are 
highly proliferative and go on to produce the hair shaft and inner root 
sheath (Hsu et al., 2014). Trp73 expression was lower in transit-amplifying 
cells during anagen II and VI (29.1% and 22.4% respectively) (Figure 4.12). 
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Figure 4.12. p73 mRNA Expression in Individual Hair Follicle Stem Cells. Bar graph of 
the percentage (%) of p73-positive cells in different classes of murine HF cells by 
single-cell RNA-seq (scRNA-seq). Hair cycle stages include: telogen, anagen I (Ana-I), 
anagen II (Ana-II), and anagen VI (Ana-VI). Cell types include: bulge HF stem cells 
(HFSC), hair germ (HG) cells, transit-amplifying cells (TAC), and dermal papilla (DP) cells. 
The number of cells analyzed for each cell type is listed above each bar. 
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Anagen VI dermal papilla cells (mesenchymal) did not express Trp73, as 
anticipated (Figure 4.12). These results indicate that Trp73 is expressed in 
HF stem cell populations during different stages of the hair cycle under 
homeostatic conditions, particularly bulge HF stem cells and hair germ 
cells.  
scRNA-seq produces data with more technical noise and biological 
variation than bulk RNA-seq (Chen et al., 2019). To validate the scRNA-
seq results, we analyzed bulk RNA-seq data from murine bulge HF and 
epidermal stem cells isolated by FACS with marker-based sorting (Itga6, 
Cd34, and Ly6a) (Ge et al., 2017). Both bulge HF and epidermal stem cells 
expressed Trp73 (Figure 4.13A), consistent with the scRNA-seq results 
(Figures 4.11C and 4.12). In order to assess TP73 expression in human 
keratinocytes, we analyzed bulk RNA-seq data from primary human 
keratinocytes (HK) cultured and differentiated in vitro (Cavazza et al., 2016; 
Kouwenhoven et al., 2015). TP73 was expressed by progenitor-enriched 
(isolated by rapid collagen IV adherence) and unenriched basal HKs, but 
not by HKs after 6 days of differentiation (Figure 4.13B), consistent with the 
p73 IF staining pattern observed in human skin (Figure 4.3A, top panel). 
These results collectively indicate that p73 is expressed by murine bulge 
HF and epidermal stem cells and basal HKs. 
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Figure 4.13. p73 mRNA Expression in Keratinocyte Populations. (A) Dot plot of Trp73 
expression (TPM) in murine bulge HF stem cells and epidermal stem cells (SC) by bulk 
RNA-seq. Cells were isolated by fluorescence-activated cell sorting (FACS) with 
marker-based sorting. Horizontal lines represent the mean. (B) Dot plot of TP73 
expression (TPM) in primary human keratinocytes (HK) grown and differentiated in vitro for 
6 or 7 days. HKs were enriched for progenitors based on rapid collagen IV adherence. 
Horizontal lines represent the mean. 
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∆Np73 Enhances p63-Mediated Expression of Keratinocyte Genes 
During Cellular Reprogramming of Human Dermal Fibroblasts to a 
Basal Keratinocyte-like State 
Prior work has shown that p73 is required for effective generation of 
iPSCs with Yamanaka factors and that iPSCs lacking p73 have an 
attenuated epithelial phenotype (Martin-Lopez et al., 2017). To study the 
role of p73 in epidermal programming, we used an induced basal 
keratinocyte (iKC) model system first described by Chen and colleagues 
(Chen et al., 2014). In this system, skin lineage-specific transcription 
factors KLF4 and ∆Np63α are expressed in neonatal human dermal 
fibroblasts (HDFn) to generate iKCs. To recapitulate the system, we 
infected HDFn cells with lentiviruses encoding KLF4, ∆Np63α, KLF4 + 
∆Np63α, or empty vector controls (Figure 4.14A). We grew the cells for 3 
days after the initial infection and performed RNA-seq. Cells infected with 
KLF4 + ∆Np63α lentivirus had increased expression of basal keratinocyte 
genes (e.g. KRT14, ITGA3) and reduced expression of fibroblast genes 
(e.g. MME, VIM) compared to control infections (Figure 4.14B). Also, the 
differentially expressed genes (n = 755) between HDFn cells infected with 
KLF4 + ∆Np63α versus control lentivirus were enriched for several 
Genome Ontology (GO) categories related to basal keratinocytes, including 
cell-substrate junction, extracellular structure organization, epidermis 
development, and epithelial cell development (Figure 4.14C). Our iKC 
results were consistent with those described in the original iKC report 
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(Chen et al., 2014), indicating that we had a reliable model system in which 
to evaluate the role of ∆Np73 in induced basal keratinocyte programming.  
 We infected HDFn cells with lentivirus encoding ∆Np73 isoforms 
(∆Np73α and ∆Np73β) or empty vector control in combination with KLF4 + 
∆Np63α and performed immunoblot analysis to verify protein expression 
(Figure 4.15A). We evaluated ∆Np73 isoforms because they are the most 
highly expressed isoforms in human skin (Chapter III, Table 3.1) and have 
been shown to regulate the initiation phase (involving mesenchymal-to-
epithelial transition) of reprogramming murine embryonic fibroblasts into 
iPSCs (Martin-Lopez et al., 2017). Three days after infection of the HDFn 
cells with ∆Np73-expressing lentivirus, we harvested cells, isolated RNA, 
and performed qRT-PCR for keratinocyte genes that are markers of the 
iKC state (KRT14, KRT5, SFN, and FLG) (Figure 4.15B). Co-expression of 
∆Np73 isoforms with KLF4 + ∆Np63α led to increased expression of 
keratinocyte genes compared to KLF4 + ∆Np63α with empty vector control 
infections (Figure 4.15B). These results imply that ∆Np73 regulates the 
expression of keratinocyte genes in coordination with ∆Np63α and, in turn, 
conversion to the iKC state. For all four genes analyzed by qRT-PCR, we 
found that ∆Np73β induced higher levels of gene expression than ∆Np73α 
(Figure 4.15B). These results are consistent with published reports of 
∆Np73β having greater transcriptional activity than ∆Np73α (Liu et al., 
2004) and suggest that the role of ∆Np73 isoforms in the iKC model is due 
to transactivation of target gene expression. 
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Figure 4.15. ∆Np73 Transcriptional Activity During iKC Reprogramming of Human 
Dermal Fibroblasts. (A) Immunoblot of KLF4, p63α, and p73 protein expression in HDFn 
cells infected with lentivirus encoding ∆Np73 isoforms (∆Np73α and ∆Np73β) or empty 
vector control in combination with KLF4 and ∆Np63α. Cells were grown for 3 days and 
protein was harvested for immunoblot analysis. (B) Bar graphs of RNA expression for the 
indicated iKC marker genes in HDFn cells infected in (A). Cells were grown for 3 days and 
RNA was harvested for qRT-PCR analysis. Expression data are represented as the fold 
increase relative to control. The mean of three replicates is shown with error bars 
representing SEM. *p-value < 0.05, **p-value < 0.01, ***p-value < 0.001. 
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 In order to identify additional ∆Np73-regulated genes in the iKC 
model system, we infected HDFn cells with lentivirus encoding ∆Np73β 
isoforms or empty vector control in combination with KLF4 + ∆Np63α. We 
used ∆Np73β because it was the strongest inducer of keratinocyte gene 
expression in our qRT-PCR experiments (Figure 4.15B). After 6 days, we 
isolated RNA from the cells and performed RNA-seq. Consistent with our 
qRT-PCR analysis (Figure 4.15B), infection of HDFn cells with ∆Np73β in 
combination with KLF4 + ∆Np63α led to increased expression of KRT14, 
KRT5, FLG, and SFN as compared to KLF4 + ∆Np63α with control or 
control alone. Also, combination infections with ∆Np73β led to increased 
expression of additional basal keratinocyte genes (e.g. ITGA3, ITGB4, 
KRT6A, KRT16, COL7A1, and CDH1) and decreased expression of 
fibroblast genes (e.g. VIM, MME, and MMP1). We performed principal 
component analysis (PCA) on the RNA-seq data and the samples 
appeared to be ordered by degree of conversion to the iKC state along 
PC1, which was responsible for the majority (88%) of the variance in the 
data (Figure 4.16A). To further investigate, we determined the top 250 
genes contributing to PC1 and plotted their expression in a heatmap 
(Figure 4.16B). We identified two main sets of PC1 genes (Figure 4.16B). 
The larger subset of genes increased in expression along PC1 and 
included many basal keratinocyte-related genes (Figure 4.16B). The 
smaller subset of genes decreased in expression along PC1 and included 
many fibroblast-related genes (Figure 4.16B). These data suggest that the 
 119 
 
Figure 4.16. ∆Np73-Regulated Genes and Pathways During iKC Reprogramming. (A) 
Principal component analysis (PCA) plot of RNA-seq from HDFn cells infected with 
lentivirus encoding ∆Np73β or empty vector control in combination with KLF4 and ∆Np63
α. Cells were grown for 6 days and RNA was harvested for RNA-seq analysis. The 
percentage (%) of variance contributed by each PC is listed in parentheses. (B) Heatmap 
of the expression of the top 250 genes contributing to PC1 from (A). (C and D) Tables 
listing the enriched Genome Ontology (GO) categories and pathways among the top 250 
genes contributing to PC1 from (A).
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10 Epithelial mesenchymal transition 1.2E-04
iKC Enriched Pathways  
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top 250 genes contributing to PC1 largely recapitulate the core genes 
involved in reprogramming to the iKC state and that ∆Np73β enhances this 
reprogramming process.  
To determine gene sets associated with reprogramming HDFn cells 
to the iKC state, we performed enrichment analysis on the top 250 PC1 
genes using WebGestalt (Wang et al., 2017). The top 20 enriched Genome 
Ontology (GO) categories included many related to keratinocytes, including 
epidermis development, skin development, extracellular structure 
organization, cornification, cell adhesion molecule-binding, and cell-cell 
junction (Figure 4.16C). Also, the top ten enriched pathways in WebGestalt 
contained many related to keratinocytes, including formation of the 
cornified envelope, extracellular matrix organization, keratinization, and cell 
junction organization (Figure 4.16D). To investigate the genes underlying 
the enriched GO categories in Figure 4.16C, we determined which of the 
top 250 PC1 genes were annotated with GO categories related to skin 
development, cell junctions, cornification, and proliferation. We identified a 
set of 44 genes involved in these biological processes that underlie most of 
the observed GO category enrichment (Figure 4.17). Of interest, we found 
that ∆Np73β increased the expression of 18 genes with known roles in 
cellular proliferation (Figure 4.17), including MKI67 and TOP2A, which is 
consistent with our data showing that p73-/- wounds have reduced 
proliferation (Figure 4.9A) and that basal proliferating cells have the highest 
percentage of p73 expression among IFE clusters (Figure 4.11C). Given 
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Figure 4.17. Core Set of 44 ∆Np73-Regulated and Skin-Associated Genes During iKC 
Reprogramming. Heatmap with the expression of a set of 44 genes that underlie the 
enrichment of GO categories observed in Figure 4.16C. Genes are annotated based on 
known roles in iKC-related processes (gray box) and the presence of a p63/p73 ChIP-seq 
peak within 50 kb of its TSS in multiple basal cell types (brown box).
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the observed delay in wound healing in p73-/- mice (Figure 4.6), we 
assessed if any of the core set of 44 genes had known roles in wound 
healing. We found that 18 of these genes have roles in wound healing, 
including ITGA3 (Reynolds et al., 2008), ITGB4 (Liu et al., 2010; Turcan et 
al., 2016), KRT6A (Wojcik et al., 2000), KRT16 (Lessard et al., 2013; Patel 
et al., 2006), COL7A1 (Nyström et al., 2013), S100A2 (Pan et al., 2018), 
AQP3 (Hara-Chikuma and Verkman, 2008), TGM1 (Inada et al., 2000), 
FERMT1 (Jobard et al., 2003; Siegel et al., 2003), and GRHL3 (Caddy et 
al., 2010) (Figure 4.17). 
To determine if p73 binds near the transcriptional start site (TSS) of 
any of the 44 genes involved in reprogramming to the iKC state, we 
analyzed p73- and p63-binding in ChIP-seq datasets from three basal cell 
models: HK [primary human keratinocytes; (Kouwenhoven et al., 2015)], 
HaCaT [immortalized keratinocyte; newly generated herein], and HCC1806 
[tumor-derived basal breast epithelial cells; newly generated herein and 
(Santos Guasch et al., 2018)]. As part of our analyses, we leveraged 
previous findings that endogenous p73 and p63 have similar genomic-
binding profiles when co-expressed (Yang et al., 2010) and that 
heterotetramers of p73 and p63 are more thermodynamically stable than 
either homotetramer (Gebel et al., 2016). We also validated the previous 
finding by Yang and colleagues (Yang et al., 2010) using our own 
HCC1806 p73 and p63 ChIP-seq data (Figure 4.18). Genes displayed in 
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Figure 4.17 were annotated as having a p63/p73 ChIP-seq peak if they met 
the following criteria: (1) had a p63/p73 ChIP-seq peak that overlapped in 
two out of the three cell types analyzed; and (2) the overlapping peak was 
located within 50 kb of the TSS of the gene and contained a canonical 
p63/p73 DNA binding motif. From the set of 44 genes involved in the iKC 
state, we found that 38 met our criteria for having a p63/p73-binding site 
(Figure 4.17). Of immediate interest were 13 of these keratinocyte-related 
genes with known roles in wound healing (Figure 4.17). Collectively, these 
findings support the conclusion that ∆Np73, in coordination with ∆Np63, 
acts as a regulator of the iKC state through direct and indirect regulation of 
key genes involved in skin development, cell junctions, cornification, 
proliferation, and wound healing.  
 
∆Np73 Enhances p63-Mediated Expression of Keratinocyte Genes 
During Induced Keratinocyte Reprogramming of Mesenchymal Breast 
Cancer Cells 
To rule out a cell-type specific phenotype and determine if ∆Np73 
could increase the expression of iKC marker genes in non-primary cells, we 
infected MDA-MB-231 cells (mesenchymal triple-negative breast cancer 
cell line) with lentivirus encoding ∆Np73 (∆Np73α and ∆Np73β) or empty 
vector control in combination with KLF4 + ∆Np63α (Figure 4.19A). After 4 
days we harvested cells, isolated RNA, and performed qRT-PCR for 
keratinocyte genes (KRT14, KRT5, FLG, and SFN) that were regulated in a 
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p73-dependent manner in HDFn cells. Expression of ∆Np73 isoforms in 
combination with KLF4 + ∆Np63α had a similar effect in MDA-MB-231 cells 
(Figure 4.19B) as it did in HDFn cells (Figure 4.15B). ∆Np73 isoforms 
increased the expression of KRT14, KRT5, FLG, and SFN; for all four of 
these genes, ∆Np73β induced higher levels of expression than ∆Np73α 
(Figure 4.19B). These results indicate that ∆Np73 isoforms can regulate the 
expression of iKC marker genes in coordination with ∆Np63α in cell types 
from different tissues of origin as well as both primary and transformed cell 
states. 
 
 126 
 
Figure 4.19. ∆Np73 Transcriptional Activity During iKC Reprogramming of 
Mesenchymal Breast Cancer Cells. (A) Immunoblot of KLF4, p63α, and p73 protein 
expression in MDA-MB-231 cells infected with lentivirus encoding ∆Np73 isoforms (∆Np73
α and ∆Np73β) or empty vector control in combination with KLF4 and ∆Np63α. Cells were 
grown for 4 days and protein was harvested for immunoblot analysis. (B) Bar graphs of 
RNA expression for the indicated iKC marker genes in MDA-MB-231 cells infected in (A). 
Cells were grown for 4 days and RNA was harvested for qRT-PCR analysis. Expression 
data are represented as the fold increase relative to control. The mean of three replicates 
is shown with error bars representing SEM. *p-value < 0.05, **p-value < 0.01.
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Conclusion 
We discovered that p73 is required for timely cutaneous wound 
healing in mice. p73-/- mice exhibited delayed wound healing, due in part to 
decreased proliferation and increased activation of the DNA damage 
response in basal keratinocytes at the epidermal wound edge. In wild-type 
mice, this same cell population exhibited increased p73 expression after 
wounding. Further, we found that p73 was expressed by epidermal and HF 
stem cells, which regulate wound healing (Ge and Fuchs, 2018). Using a 
model system for reprogramming fibroblasts to keratinocyte-like cells, we 
found that ∆Np73, in conjunction with ∆Np63, regulates the expression of 
keratinocyte genes and conversion to a keratinocyte-like state. We 
identified a core set of 44 genes directly or indirectly regulated by ∆Np73 
that are involved in skin development, cell junctions, cornification, 
proliferation, and wound healing. 
Our study provides insight to the role of p73 in basal keratinocytes 
and the skin overall and highlights the importance of studying the functional 
interplay of p73 and p63. Our results provide a mechanism for the wound 
healing phenotype observed in p73-/- mice and build on observations from 
previous studies linking ∆Np73 to stem cell activity in the basal cells of the 
(Lin et al., 2012; Martin-Lopez et al., 2017) trachea (Marshall et al., 2016), 
iPSCs (Lin et al., 2012; Martin-Lopez et al., 2017), neural stem cells (Talos 
et al., 2010), and cancer stem cells (Meier et al., 2016). We propose a 
model in which ∆Np73 is required for effective function of adult skin stem 
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cells after stress, through coordinate regulation with ∆Np63 of a progenitor 
cell transcriptional program. 
 
  
 129 
CHAPTER V 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Introduction 
The work presented within this dissertation was carried out with the 
goal of expanding our knowledge of the biological roles of p73 in basal 
epithelial cells, the stem cell population of many tissues. The primary 
impetus for the work was a discovery made during our prior study linking 
p73 to multiciliogenesis (Marshall et al., 2016), namely, that p73 is 
expressed by basal epithelial cells in the murine trachea and that tracheas 
from p73-/- mice exhibit a 35% reduction in the number of basal epithelial 
cells number despite a loss of multiciliated cells, the most common cell type 
in the tissue. These data imply that basal cell maintenance and 
differentiation are regulated by loss of p73. Findings from previous studies 
support this implication: (1) p73 is expressed by basal epithelial cells in 
many tissue types (Puig et al., 2003); and (2) p73 regulates stem cell 
maintenance and/or activity in a variety of biological contexts (Agostini et 
al., 2010; Alexandrova et al., 2013; Gonzalez-Cano et al., 2010; Lin et al., 
2012; Martin-Lopez et al., 2017; Rufini et al., 2012; Talos et al., 2010), 
including basal epidermal stem cells (Sada et al., 2016). With these 
findings in mind, we decided to focus on the basal epithelial cells in the 
skin. 
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Determining which p73 isoforms are expressed in a given cell or 
tissue model is an important step in deciphering the functional roles of p73 
in the model because the proteins encoded by different p73 isoforms have 
distinct biological properties (Nemajerova et al., 2016; Romano et al., 2012; 
Su et al., 2009; Wilhelm et al., 2010). In Chapter III, I presented our 
methodology to quantify p73 isoform expression, through analysis of exon 
junction-spanning reads corresponding to alternative promoter usage and 
splicing isoforms, and used it to analyze the largest publicly available RNA-
seq dataset of human tissue. In the skin, we determined that ΔNp73 is the 
predominantly expressed isoform. 
In Chapter IV, I described the findings from a series of experiments 
designed to evaluate the role of p73 in basal keratinocyte function. We 
showed that p73-deficient mice exhibit delayed wound healing despite 
morphologically normal-appearing skin. The delay in wound healing was 
accompanied by decreased proliferation in basal keratinocytes at the 
epidermal wound edge. In wild-type mice, this same cell population 
exhibited increased p73 expression after wounding. Through analysis of 
transcriptomic data, we found that p73 was expressed by epidermal and 
hair follicle stem cells, cell types required for wound healing. Moreover, 
using a model to reprogram fibroblasts into keratinocyte-like cells (iKC), we 
discovered that ΔNp73 regulates the expression of a gene network 
involved in wound healing, proliferation, and skin development. Collectively, 
our data establish a role for p73 in cutaneous wound healing, in part 
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through regulation of genes with roles in timely wound healing and 
proliferation. In the remainder of this Chapter, I discuss questions that arise 
from our findings and describe hypotheses that can be experimentally 
tested to further our understanding of the roles and regulation of p73 in 
basal keratinocytes and, more broadly, in basal epithelial cells. 
  
p73 and Stem Cells 
Adult tissue stem cells have an important role in tissue maintenance 
and regeneration after injury (Ermolaeva et al., 2018). The stem cell 
function of these long-lived cells decreases with age due to the 
accumulation of cellular damage and contributes to the declining functional 
capacities observed in aging tissues (Ermolaeva et al., 2018). The delayed 
healing, reduced proliferation, and increased levels of the DNA damage 
response observed in the epidermal wounds of p73-/- mice implies that p73 
regulates the activity of adult skin stem cells after injury. While we did not 
detect an overt difference in the morphology or the expression pattern of 
epidermal differentiation markers in the skin of adult p73-/- mice, we cannot 
rule out that p73 also regulates adult skin stem cells during homeostasis, 
which in turn could impact the functional abilities of these cells after injury. 
A role for p73 in the regulation of adult stem cells is consistent with 
previous studies showing that p73 regulates neural stem cell maintenance 
(Agostini et al., 2010; Talos et al., 2010) and protects against aging through 
regulation of cellular metabolism and the oxidative stress response (Du et 
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al., 2013; Marini et al., 2018; Rufini et al., 2012). Additional studies utilizing 
alternate wounding (e.g. partial-thickness wounding) and genetic (e.g. p73 
isoform-specific knockout mice) models will be needed to further explore 
the roles of p73 in adult skin stem cells. Questions still unanswered include: 
(1) What roles does p73 play in epidermal and HF stem cells after injury 
and how do they differ between the cell types?; (2) What is the relative 
contribution of p73 isoforms to the wound healing phenotypes observed in 
p73-/- mice?; (3) Does p73 have any roles in stem cell maintenance in the 
skin, similar to p63 (Su et al., 2009; Yang et al., 1999)?; and (4) What role, 
if any, does p73 have regulation of the immune system response during 
wound healing? Based on the increased p73 staining at post-wound day 3 
in the newly-formed wound epidermis, a time point at which basal 
keratinocytes are migrating into the wound to close the gap, and recent 
work demonstrating that p73 regulates migration(Fernandez-Alonso et al., 
2015; Santos Guasch et al., 2018), we hypothesize that p73 also regulates 
the migration of keratinocytes during epithelialization. 
  
Interplay of p73 and p63 
Through analysis of single cell expression in the skin (IF and 
scRNA-seq), we observed that nearly all p73-positive basal keratinocytes 
co-expressed p63. Since p73 and p63 can hetero-oligomerize (Davison et 
al., 1999; Gebel et al., 2016), it is difficult to properly study the function of 
p73 in these cells without also taking into account p63. Moving forward, it is 
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important to characterize p73 and p63 isoform expression at the cellular 
level in order to better understand the interplay between these family 
members and how they vary between individual cells. Our ability to study 
p73 isoform expression in the single-cell analyses was limited by the low 
number of exon-exon spanning reads from the 5’ end of mRNA transcripts 
in current scRNA-seq data sets and the lack of p73 isoform-specific 
antibodies. From our analysis of GTEx data, we determined that ∆Np73 is 
the most highly expressed N-terminal isoform (both α and β) in adult 
human skin during homeostasis. Further studies are needed to determine if 
p73 isoform expression patterns vary amongst cell types in the skin (e.g. 
epidermal versus HF stem cells) and if ∆Np73 is the predominantly 
expressed isoform in basal cells across tissue types. If the latter is 
confirmed, it is tempting to posit that p73 isoform switching might be 
involved in signaling tracheal basal cells (∆Np73+) to differentiate into 
multiciliated cells (TAp73+) (Marshall et al., 2016). 
In our experiments reprogramming fibroblasts into keratinocyte-like 
cells, we discovered that ∆Np73 isoforms, in particular ∆Np73β, 
significantly enhanced the expression of keratinocyte genes (e.g. KRT14, 
KRT5) and conversion to a keratinocyte-like state. Rather than causing 
gene expression changes in unique genes like KLF4, ∆Np73 largely 
amplified the magnitude of ∆Np63-induced gene expression, suggesting 
that ∆Np73 and ∆Np63 have similar transcriptional activity in this context. 
We observed similar results in reprogramming MDA-MB-231 cells, 
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suggesting that this phenotype is not cell-type specific. Similarly, while 
validating the iKC model, we found that KLF4 significantly enhanced the 
expression of genes that were differentially expressed in ∆Np63-only 
conditions. Going forward, it will be important to determine how interplay 
between KLF4, ∆Np63, and ∆Np73 affects target gene regulation, as all 
three transcription factors are co-expressed by basal keratinocytes, and 
how ∆Np73 has such large effects on target gene expression in the iKC 
model system. Among the top ∆Np73-regulated genes, we identified an 
enrichment for genes involved in proliferation and wound healing; this 
knowledge may be useful in studying the mechanisms underlying the 
wound healing defect in p73-/- mice. Additional studies will be required to 
determine which of the ∆Np73-regulated genes are novel direct target 
genes in basal keratinocytes, as our analysis was limited to identifying 
genes that contained overlapping p63/p73 genomic-binding sites within 50 
kb of the TSS in multiple basal cell types. In future studies, it will be 
important to determine the role of TAp73 isoforms in the iKC model system 
and the skin more broadly, since these isoforms are generally more 
transcriptionally active, expressed in human skin, and deleted along with 
∆Np73 isoforms in our p73-/- mice with the wound healing defect. Our 
reprogramming studies are limited by their in vitro nature and reliance on 
ectopic overexpression of lineage-specific transcription factors; 
nevertheless, the results are of significant value since they provide insight 
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to the interplay between p73 and p63 in driving a keratinocyte-like 
transcriptional program. 
Ankyloblepharon-ectodermal defects-cleft lip/palate (AEC) 
syndrome, a rare ectodermal dysplasia caused by heterozygous mutations 
in the C-terminus of TP63, is distinguished from other human TP63-
associated disorders by the occurrence of severe skin erosions, especially 
those of the scalp (Julapalli et al., 2009; McGrath et al., 2001). A recent 
study determined that this unique symptom is due to the increased 
propensity of AEC-mutant p63 protein to aggregate intracellularly (Russo et 
al., 2018). Interestingly, the authors found that AEC-mutant p63 bound to 
and coaggregated with p73, likely inhibiting its transcriptional activity. The 
overlapping functions between ∆Np73 and ∆Np63 in our studies with the 
iKC model system provide a potential explanation for the severe skin 
phenotype observed in patients with AEC syndrome. Namely, the skin 
erosions are more severe in patients with AEC syndrome because they 
impaired function of both p63 and p73. Analogously, the lack of an overt 
phenotype in the skin of p73-/- mice during homeostasis might be due to 
the ability of p63, which is more highly expressed, to compensate for the 
loss of p73. In future studies, it would be interesting to determine if 
expression of ∆Np73 from the endogenous ∆Np63 promotor could rescue 
the ectodermal development defects observed in p63-/- mice. These 
studies would help clarify the biological differences between ∆Np63 and 
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∆Np73 beyond differential regulation of mRNA expression levels in different 
tissues and cell types.  
 
p73 mRNA Isoform Quantification 
Our p73 mRNA isoform analysis provided preliminary evidence 
consistent with the existence of a previously unreported p73 TSS located 
upstream of the ‘5 end of exon 4 that may be expressed in multiple 
epithelial tissue types. Further experiments using alternate methods (e.g. 
CAGE sequencing, DNase I mapping, H3K4me3 ChIP-seq, mass 
spectrometry) will be required to definitely prove the TSS exists in vivo. If 
confirmed, this finding could catalyze the reinterpretation of studies 
comparing global p73-/- to TAp73-/- and ∆Np73-/- mouse models. 
Experiments designed to study the mechanistic and biological differences 
between ∆Np73 and E4p73 should be performed in physiologically-relevant 
contexts, and analyzed with and without ∆Np63 co-expressed, since most 
of the tissue types with evidence supporting E4p73 also co-express ∆Np63. 
A previous study reported that the first 13 amino acids of ∆Np73 play 
important roles in transcriptional regulation at canonical p53 target genes 
(Liu et al., 2004) and these amino acids would be absent from E4p73. 
Rinne and colleagues identified three patients with an AEC-like syndrome, 
caused by mutations in the exons of TP63 that encode the ∆N domain, that 
express a truncated ∆Np63 protein (termed ∆∆Np63) analogous to E4p73 
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with reduced transcriptional activity at the KRT14 promoter (Rinne et al., 
2008). 
 
Conclusions 
In conclusion, the research presented herein has uncovered a new 
role for p73 in the basal keratinocytes of the skin and provided insight into 
the co-regulation of gene expression by ∆Np63 and ∆Np73 when co-
expressed by cells. Our work builds on prior studies link p73 to stem cells 
and supports a model in which ∆Np73 is required for effective function of 
adult skin stem cells after stress, through coordinate regulation with ∆Np63 
of a progenitor cell transcriptional program. We hope this work will be 
valuable to the p53 family, skin biology, and stem cell fields and that our 
discoveries can be translated into improved outcomes for human diseases 
with potential links to p73 function such as cancer, COPD, infertility, and 
ectodermal dysplasia syndromes. 
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